

GENENTECH INC
Form 10-Q
July 23, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2003

or

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____ to _____ .

Commission file number: 1-9813

GENENTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

94-2347624

(State or other jurisdiction
of incorporation or organization)

(I.R.S. Employer
Identification Number)

1 DNA Way, South San Francisco, California 94080-4990

(Address of principal executive offices and Zip Code)

(650) 225-1000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No []

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes [x] No []

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

<u>Class</u>	<u>Number of Shares Outstanding</u>
Common Stock \$0.02 par value	517,848,951 Outstanding at June 30, 2003

GENENTECH, INC.
TABLE OF CONTENTS

	<u>Page No.</u>
<u>PART I - FINANCIAL INFORMATION</u>	
Item 1.	
	<u>Financial Statements</u>
	<u>Condensed Consolidated Statements of Operations - for the three and six months ended June 30, 2003 and 2002</u> 3
	<u>Condensed Consolidated Statements of Cash Flows - for the six months ended June 30, 2003 and 2002</u> 4
	<u>Condensed Consolidated Balance Sheets - June 30, 2003 and December 31, 2002</u> 5
	<u>Notes to Condensed Consolidated Financial Statements</u> 6-17
	<u>Independent Accountants' Review Report</u> 18
Item 2.	19-46
	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
Item 3.	47
	<u>Quantitative and Qualitative Disclosures About Market Risk</u>
Item 4.	47
	<u>Controls and Procedures</u>
<u>PART II - OTHER INFORMATION</u>	

Item 1.		48
	<u>Legal Proceedings</u>	
Item 4.		48-49
	<u>Submission of Matters to a Vote of Security Holders</u>	
Item 6.		49
	<u>Exhibits and Reports on Form 8-K</u>	
		50
	<u>SIGNATURES</u>	

In this report, "Genentech," "we," "us" and "our" refer to Genentech, Inc. "Common Stock" refers to Genentech's common stock, par value \$0.02 per share and "Special Common Stock" refers to Genentech's callable puttable common stock, par value \$0.02 per share, all of which was redeemed by Roche Holdings, Inc. on June 30, 1999.

We own or have rights to various copyrights, trademarks and trade names used in our business including the following: Activase® (alteplase, recombinant) tissue-plasminogen activator; Avastin™ (bevacizumab) anti-VEGF antibody; Cathflo® Activase® (alteplase for catheter clearance); Herceptin® (trastuzumab) anti-HER2 antibody; Lucentis™ (ranibizumab, rhuFab V2) anti-VEGF antibody fragment; Nutropin® (somatropin (rDNA origin) for injection) growth hormone; Nutropin AQ® and Nutropin AQ Pen™ (somatropin (rDNA origin) for injection) liquid formulation growth hormone; Nutropin Depot® (somatropin (rDNA origin) for injectable suspension) encapsulated sustained-release growth hormone; Protropin® (somatrem for injection) growth hormone; Pulmozyme® (dornase alfa, recombinant) inhalation solution; TNKase™ (tenecteplase) single-bolus thrombolytic agent; and Raptiva™ (efalizumab, formerly Xanelim™) anti-CD11a antibody. Rituxan® (rituximab) anti-CD20 antibody is a registered trademark of IDEC Pharmaceuticals Corporation; Tarceva™ (erlotinib) is a trademark of OSI Pharmaceuticals, Inc.; and Xolair® (omalizumab) anti-IgE antibody is a trademark of Novartis AG. This report also includes other trademarks, service marks and trade names of other companies.

Page 2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

GENENTECH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

Three Months
Ended June 30,

Six Months
Ended June 30,

Edgar Filing: GENENTECH INC - Form 10-Q

	2003	2002	2003	2002
Revenues:				
Product sales (including amounts from related party:				
three months - 2003-\$35,775;	644,324	523,527	\$ 1,242,806	\$ 1,000,077
2002-\$31,318;				
six months - 2003-\$65,184;				
2002-\$52,665)	\$	\$		
Royalties (including amounts from related party:				
three months - 2003-\$57,577;	122,786	85,535	236,061	167,378
2002-\$33,425;				
six months - 2003-\$104,464;				
2002-\$59,275)				
Contract revenue (including amounts from related parties:				
three months - 2003-\$18,415;		13,181	70,517	22,871
2002-\$4,842;				
six months - 2003-\$20,703;				
2002-\$8,653)	32,602			
Total operating revenues	799,712	622,243	1,549,384	1,190,326
Costs and expenses				
Cost of sales (including amounts for related party:				
three months - 2003-\$30,014;		106,867	238,249	209,311
2002-\$26,061;				
six months - 2003-\$54,843;				
2002-\$44,884)	123,407			
Research and development (including contract related:				
three months - 2003-\$16,980;		147,922	337,636	294,613
2002-\$7,126;				
six months - 2003-\$26,452;				
2002-\$11,576)	180,203			
Marketing, general and administrative	184,258	125,671	321,480	241,091
Collaboration profit sharing	107,307	84,090	203,854	156,168
Recurring charges related to redemption	38,586	38,928	77,172	77,856
Special charges: Litigation-related	13,363	518,000	26,608	518,000
Total costs and expenses	647,124	1,021,478	1,204,999	1,497,039
Operating margin (loss)	152,588	(399,235)	344,385	(306,713)
Other income, net	40,870	28,825	56,573	65,234

Edgar Filing: GENENTECH INC - Form 10-Q

Income (loss) before taxes	193,458	(370,410)	400,958	(241,479)
Income tax provision (benefit)	61,113	(156,762)	117,143	(123,134)
Net income (loss)	\$ 132,345	\$ (213,648)	\$ 283,815	\$ (118,345)

Earnings (loss) per share

:

Basic	\$ 0.26	\$ (0.41)	\$ 0.55	\$ (0.23)
Diluted	\$ 0.25	\$ (0.41)	\$ 0.55	\$ (0.23)

Weighted-average shares used to compute basic earnings (loss) per share:

Basic	512,909	520,001	512,398	523,361
Diluted	522,914	520,001	520,102	523,361

See Notes to Condensed Consolidated Financial Statements.

Page 3

GENENTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended June 30,	
	2003	2002
Cash flows from operating activities:		
Net income (loss)	\$ 283,815	\$ (118,345)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
Depreciation and amortization	144,871	136,245
Deferred income taxes	(30,109)	(213,256)
Gains on sales of securities available-for-sale	(19,605)	(34,476)

Edgar Filing: GENENTECH INC - Form 10-Q

Losses on sales of securities available-for-sale	765	3,775
Write-down of securities available-for-sale	3,764	9,451
Loss on fixed asset dispositions	2,408	9,125
Changes in assets and liabilities:		
Litigation-related liability	27,855	518,000
Investments in trading securities	(17,457)	(109,959)
Other current assets	2,618	(40,448)
Account receivable, trade	(28,086)	21,803
Account receivable, royalties	(24,270)	10,488
Account receivable, other	(208,619)	(8,084)
Inventories	(28,872)	(23,251)
Accounts payable, other current liabilities and other long-term liabilities	297,182	28,184
Net cash provided by operating activities	406,260	189,252
Cash flows from investing activities:		
Purchases of securities available-for-sale	(575,354)	(460,615)
Proceeds from sales and maturities of securities available-for-sale	304,300	768,427
Capital expenditures	(140,145)	(163,816)
Change in other assets	(32,774)	(11,632)
Net cash (used in) provided by investing activities	(443,973)	132,364
Cash flows from financing activities:		
Stock issuances	285,333	43,704
Stock repurchases	(195,274)	(491,212)
Repayment of short-term debt	-	(149,692)
Net cash provided by (used in) financing activities	90,059	(597,200)
Net increase (decrease) in cash and cash equivalents	52,346	(275,584)
Cash and cash equivalents at beginning of period	208,130	395,203
Cash and cash equivalents at end of period	<u>\$ 260,476</u>	<u>\$ 119,619</u>
Supplemental cash flow data:		
Cash paid during the year for:		
Interest	\$ -	\$ 7,482
Income taxes paid	150,250	86,911

See Notes to Condensed Consolidated Financial Statements.

GENENTECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

	June 30, 2003	December 31, 2002
Assets:		
Current assets:		
Cash and cash equivalents	\$ 260,476	\$ 208,130
Short-term investments	955,337	826,442
Accounts receivable - product sales, net (including amounts due from related party: 2003-\$11,324; 2002-\$18,564)	270,993	242,907
Accounts receivable - royalties, net (including amounts due from related party: 2003-\$81,164; 2002-\$60,615)	140,693	116,423
Accounts receivable - other, net (including amounts due from related parties: 2003-\$262,564; 2002-\$27,715)	267,770	59,151
Inventories	422,414	393,542
Prepaid expenses and other current assets	234,597	236,189
Total current assets	2,552,280	2,082,784
Long-term marketable securities and other	785,877	567,286
Property, plant and equipment (net of accumulated depreciation: 2003-\$771,590; 2002-\$727,612)	1,146,875	1,068,734
Goodwill	1,334,219	1,334,219
Other intangible assets (net of accumulated amortization: 2003-\$1,663,817; 2002-\$1,578,884)	865,719	927,538
Restricted cash	686,600	686,600
Other long-term assets	106,745	110,158
Total assets	\$ 7,478,315	\$ 6,777,319
Liabilities and stockholders' equity:		
Current liabilities:		
Accounts payable	\$ 69,215	\$ 51,380

Other accrued liabilities (including amounts due to related parties: 2003-\$52,495; 2002-\$51,116)	529,506	595,280
Total current liabilities	598,721	646,660
Litigation-related liabilities	580,040	552,185
Deferred revenue and other long-term liabilities	446,621	239,590
Total liabilities	1,625,382	1,438,435
Commitments and contingencies		
Stockholders' equity:		
Preferred stock	-	-
Common stock	10,357	10,256
Additional paid-in capital	6,990,075	6,650,352
Accumulated deficit, since June 30, 1999	(1,431,120)	(1,590,366)
Accumulated other comprehensive income	283,621	268,642
Total stockholders' equity	5,852,933	5,338,884
Total liabilities and stockholders' equity	\$ 7,478,315	\$ 6,777,319

See Notes to Condensed Consolidated Financial Statements.

GENENTECH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of adjustments of a normal recurring nature) considered necessary for a fair presentation have been included. Operating results for the three- and six-month periods ended June 30, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003. The Condensed Consolidated Balance Sheet as of December 31, 2002 has been derived from the audited consolidated financial statements as of that date. For further information, refer to the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended

December 31, 2002.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States (or U.S.) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In November 2002, the Emerging Issues Task Force (or EITF) of the Financial Accounting Standards Board (or FASB) issued EITF 00-21, "Revenue Arrangements with Multiple Deliverables," which addresses certain aspects of the accounting for arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. Under EITF 00-21, revenue arrangements with multiple deliverables should be divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration should be allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria should be considered separately for each of the separate units of accounting. EITF 00-21 is effective for revenue arrangements we enter into after June 30, 2003. We are currently evaluating the impact of EITF 00-21 on revenue arrangements we enter into in the future, which will need to comply with EITF 00-21.

In November 2002, the FASB issued Interpretation No. 45 (or FIN 45), "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN 45 elaborates on the existing disclosure requirements for most guarantees, including residual value guarantees issued in conjunction with operating lease agreements. It also clarifies that at the time a company issues a guarantee, the company must recognize an initial liability for the fair value of the obligation it assumes under that guarantee and must disclose that information in its interim and annual financial statements. The initial recognition and measurement provisions apply on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. Our adoption of FIN 45 did not have a material impact on our results of operations and financial position. See Note 2, "Leases and Contingencies," below for a discussion of our exposure related to our agreement with Serono S.A. and our synthetic leases and the related residual value guarantees.

In January 2003, the FASB issued Interpretation No. 46 (or FIN 46), "Consolidation of Variable Interest Entities." FIN 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. A variable interest entity is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A variable interest entity often holds financial assets, including loans or receivables, real estate or other property. A variable interest entity may be essentially passive or it may engage in research and development or other activities on behalf of another entity. The consolidation requirements of FIN 46 apply to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply to all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. See Note 2, "Leases and Contingencies," below for a discussion

of our synthetic leases and the expanded disclosures required by FIN 46.

In December 2002, the FASB issued Statement No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." FAS 148 amends FAS 123 "Accounting for Stock-Based Compensation" to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The additional disclosure requirements of FAS 148 are effective for fiscal years ending after December 15, 2002. We have elected to continue to follow the intrinsic value method of accounting as prescribed by Accounting Principles Board Opinion No. 25 (or APB 25), "Accounting for Stock Issued to Employees," to account for employee stock options. Under APB 25, no compensation expense is recognized unless the exercise price of our employee stock options is less than the market price of the underlying stock on the date of grant. We have not recorded such expense in the periods presented because we grant options at the fair market value of the underlying stock on the date of grant.

We currently grant options under a stock option plan, which allows for the granting of non-qualified stock options, stock awards and stock appreciation rights to employees, directors and consultants of Genentech. Incentive stock options may only be granted to employees under this plan. Generally, non-qualified options have a maximum term of 10 years. Incentive options have a maximum term of 10 years. In general, options vest in increments over four years from the date of grant, although we may grant options with different vesting terms from time to time. No stock appreciation rights or incentive stock options have been granted under our current plan to date.

We have an employee stock plan that allows eligible employees to purchase Common Stock at 85% of the lower of the fair market value of the Common Stock on the grant date or the fair market value on the first business day of each calendar quarter. Purchases are limited to 15% of each employee's eligible compensation. All full-time employees of Genentech are eligible to participate in this plan.

The following information regarding net income (loss) and earnings (loss) per share has been determined as if we had accounted for our employee stock options and employee stock plan under the fair value method prescribed by FAS 123. The resulting effect on net income (loss) and earnings (loss) per share pursuant to FAS 123 is not likely to be representative of the effects in future periods, due to subsequent additional option grants and periods of vesting. The fair value of options was estimated at the date of grant using a Black-Scholes option valuation model with the following weighted-average assumptions:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Risk-free interest rate	2.0%	4.3%	2.3%	4.3%
Dividend yield	0.0%	0.0%	0.0%	0.0%
Volatility factors of the expected market price of our Common Stock	45.0%	43.0%	40.8%	43.0%
Weighted-average expected life of option (years)	5	5	5	5

The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because our employee stock options have characteristics significantly different from those of traded options and changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not provide a reliable single measure of the fair value of our employee stock options.

For purposes of disclosures pursuant to FAS 123 as amended by FAS 148, the estimated fair value of options is amortized to expense ratably over the options' vesting period.

The following table illustrates the effect on reported net income (loss) and earnings (loss) per share as if we had applied the fair value recognition provisions of FAS 123 to stock-based employee compensation (in thousands, except per share amounts):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Net income (loss) - as reported	\$ 132,345	\$ (213,648)	\$ 283,815	\$ (118,345)
Deduct: Total stock-based employee compensation expense determined under the fair value based method for all awards, net of related tax effects	40,440	44,274	81,431	88,942
Pro forma net income (loss)	\$ 91,905	\$ (257,922)	\$ 202,384	\$ (207,287)
Earnings (loss) per share:				
Basic-as reported	\$ 0.26	\$ (0.41)	\$ 0.55	\$ (0.23)
Basic-pro forma	\$ 0.18	\$ (0.50)	\$ 0.39	\$ (0.40)
Diluted-as reported	\$ 0.25	\$ (0.41)	\$ 0.55	\$ (0.23)
Diluted-pro forma	\$ 0.18	\$ (0.50)	\$ 0.39	\$ (0.40)

Accounts Receivable Allowances

We prepare estimates for discounts, rebates and sales returns and allowances based primarily on historical trends and experience and changes in customer financial conditions.

Reclassifications

In the three and six months ended June 30, 2003, we made certain classification changes in our Condensed Consolidated Statements of Operations. A new caption titled "other income, net" was added to the Condensed

Consolidated Statements of Operations (see below for the composition of this new caption). The "contract and other" caption presented in prior periods was changed to "contract revenues" and the gains from the sale of biotechnology equity securities that were previously included in "contract and other" are now reflected in "other income, net." In addition, write-downs on biotechnology equity securities previously included in "marketing, general and administrative" expenses are now also reflected in the "other income, net" caption.

The following table summarizes the components of "other income, net" (in thousands):

Other Income, Net	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Gains on sales of biotechnology equity securities	\$ 19,675	\$ 105	\$ 20,217	\$ 17,180
Write-downs of biotechnology debt and equity securities	-	(1,244)	(3,764)	(9,451)
Interest income	21,195	29,964	40,120	58,258
Interest expense	-	-	-	(753)
Total other income, net	\$ 40,870	\$ 28,825	\$ 56,573	\$ 65,234

As part of our strategic alliance efforts, we invest in debt and equity securities of certain biotechnology companies with which we have or have had collaborative agreements. "Other income, net" in the Condensed Consolidated Statements of Operations includes realized gains and losses from the sale of certain of these biotechnology equity securities and write-downs for other-than-temporary declines in the fair value of certain of these biotechnology debt and equity securities. In addition, "other income, net," includes interest income and interest expense, net of amounts capitalized.

Certain other reclassifications of prior year amounts have been made to our Condensed Consolidated Statements of Operations and our Condensed Consolidated Balance Sheets to conform with the current year presentation.

Note 2. LEASES AND CONTINGENCIES

Leases

We lease various real properties under operating leases that generally require us to pay taxes, insurance, maintenance and minimum lease payments. Some of our leases have options to renew. Four of our operating leases are commonly referred to as synthetic leases. A synthetic lease represents a form of off-balance sheet financing under which an unrelated third-party funds 100% of the costs of the acquisition and/or construction of the property and leases the asset to a lessee (Genentech), and at least 3% of the third-party funds represent at-risk equity. As the lessee, our synthetic leases are treated as operating leases for accounting purposes and as financing leases for tax purposes. (See also below regarding FIN 46). Under our synthetic lease structures, upon termination or expiration, at our option,

we must either purchase the property from the lessor at a predetermined amount that does not constitute a purchase at less than fair market value, sell the real property to a third-party, or renew the lease arrangement. If the property is sold to a third-party at an amount less than the amount financed by the lessor, we have agreed under residual value guarantees to pay the lessor up to an agreed upon percentage of the amount financed by the lessor.

Three of our four synthetic leases were entered into with BNP Paribas Leasing Corporation (or BNP), who leases directly to us various buildings that we occupy in South San Francisco, California. Under certain of these leases, we are required to maintain cash collateral of \$56.6 million, which we have included in our Condensed Consolidated Balance Sheets as restricted cash.

The most significant of our synthetic leases relates to our manufacturing facility located in Vacaville, California. In November 2001, we completed a synthetic lease transaction for this facility, which had previously been leased to us under a predecessor synthetic lease. This new synthetic lease is structured differently from our other synthetic leases. As the lessee, we lease the property from an unrelated special purpose trust (owner/lessor) under an operating lease agreement for five years ending November 2006. Third-party financing is provided in the form of a 3% at-risk equity participation from investors and 97% debt commitment. Investors' equity contributions were equal to or greater than 3% of the fair value of the property at the lease's inception and are required to remain so for the term of the lease. A bankruptcy-remote, special purpose corporation (SPC) was formed to fund the debt portion through the issuance of commercial paper notes. The SPC lends the proceeds from the commercial paper to the owner/lessor, who issues promissory notes to the SPC. The SPC loans mature in November 2006. The SPC promissory notes are supported by a credit facility provided by financing institutions and draws are generally available under that credit facility to repay the SPC's commercial paper. The collateral for the SPC loans includes the leased property, and an interest in the residual value guarantee provided by us. As the lessee, at any time during the lease term, we have the option to purchase the property at an amount that does not constitute a purchase at less than fair market value. Our off-balance sheet contingent liability under the residual value guarantees is summarized in the table below.

Under all the synthetic leases, Genentech, as the lessee, is also required to maintain certain pre-defined financial ratios and is limited to the amount of debt it can assume. In addition, no Genentech officer or employee has any financial interest with regard to these synthetic lease arrangements or with any of the special purpose entities used in these arrangements. In the event of a default, the maximum amount payable under the residual value guarantee would equal 100% of the amount financed by the lessor, and our obligation to purchase the leased

properties or pay the related residual value guarantees could be accelerated. We believed at the inception of the leases and continue to believe that the occurrence of any event of default that could trigger our purchase obligation is remote.

Future minimum lease payments under operating leases, exclusive of the residual value guarantees, executory costs and sublease income, at December 31, 2002, are as follows (in millions). These minimum lease payments were computed based on interest rates current at that time, which are subject to fluctuations in certain market-based interest rates:

	2003	2004	2005	2006	2007	Thereafter	Total
Synthetic leases	\$ 9.6	\$ 9.4	\$ 8.8	\$ 8.8	\$ 1.3	\$ -	\$ 37.9
Other operating leases	4.8	3.3	3.1	2.6	2.4	5.2	21.4

Edgar Filing: GENENTECH INC - Form 10-Q

Total	\$ 14.4	\$ 12.7	\$ 11.9	\$ 11.4	\$ 3.7	\$ 5.2	\$ 59.3
-------	---------	---------	---------	---------	--------	--------	---------

The following summarizes the approximate assumed carrying values of the leased properties as of December 31, 2002, which represents the initial fair values of the facilities at the inception of the related leases, less assumed depreciation through June 30, 2003, and residual value guarantee amounts for our synthetic leases (in millions):

	Approximate Initial Fair Value of Leased Property	Estimated Accumulated Depreciation	Estimated Carrying Value	Lease Expiration	Maximum Residual Value Guarantee
South San Francisco Lease 1	\$ 56.6	\$ 21.4	\$ 35.2	07/2004	\$ 48.1
South San Francisco Lease 2	152.0	29.2	122.8	06/2007	129.2
South San Francisco Lease 3	25.0	4.9	20.1	01/2004	21.3
Vacaville Lease	425.0	66.0	359.0	11/2006	371.8
Total	\$ 658.6	\$ 121.5	\$ 537.1		\$ 570.4

We believe that there have been no impairments in the fair value or use of the properties that we lease under synthetic leases wherein we believe that we would be required to pay amounts under any of the residual value guarantees. We will continue to assess the fair values of the underlying properties and the use of the properties for impairment at least annually.

The maximum exposure to loss on our synthetic leases include (i) residual value guarantee payments as shown above, (ii) certain tax indemnifications in the event the third-parties are obligated for certain federal, state or local taxes as a result of their participation in the transaction, and (iii) indemnification for various losses, costs and expenses incurred by the third-party participants as a result of their ownership of the leased property or participation in the transaction, and as a result of the environmental condition of the property. The additional taxes, losses and expenses as described in (ii) and (iii) are contingent upon the existence of certain conditions and, therefore, would not be quantifiable at this time. However, we do not expect these additional taxes, losses and expenses to be material. In the case of Lease 1, we have pledged cash collateral of \$56.6 million as a source of payment for Genentech's obligation for the residual value guarantee payments and other amounts we owe under the lease.

Under FIN 46, synthetic leasing structures that qualify as variable interest entities are required to be consolidated by the primary beneficiary. We have determined that, the leasing structure used in the Vacaville Lease qualifies as a variable interest entity under FIN 46. Accordingly, with respect to our Vacaville Lease, we have determined that effective July 1, 2003, we will need to consolidate assets of approximately \$359.0 million, net of accumulated depreciation, liabilities of approximately \$412.3 million and noncontrolling interests of approximately \$12.7 million, and we expect to record a charge of approximately \$39.6 million, net of tax, as a cumulative effect of an accounting change on July 1, 2003. We are in the process of finalizing our assessment of the related fair values, which may vary from the actual fair values we record upon adoption. With regard to BNP Leases 1, 2 and 3, we have determined that these leases do not qualify as variable interest entities and accordingly, we will not be required to consolidate the related assets and liabilities under FIN 46 on July 1, 2003.

Contingencies

In August 2002, we entered into an agreement with Serono S.A. to market Raptiva internationally outside the United States, Japan, and certain other Asian countries. In February 2003, we amended the agreement with Serono to expand Serono's marketing rights to include certain additional Asian countries other than Japan. Development and marketing rights in the United States remain with us and our U.S. collaborator, XOMA (US) LLC, and we retain exclusive marketing rights in Japan. Under the agreement, we and Serono may collaborate on co-developing additional indications of Raptiva and will share certain global development costs. In addition, we have a supply agreement with Serono under which we could have a loss exposure up to a maximum of \$10.0 million.

We are a party to various legal proceedings, including patent infringement litigation relating to our antibody products, and licensing and contract disputes, and other matters.

We and the City of Hope Medical Center are parties to a 1976 agreement relating to work conducted by two City of Hope employees, Arthur Riggs and Keiichi Itakura, and patents that resulted from that work, which are referred to as the "Riggs/Itakura Patents." Since that time, Genentech has entered into license agreements with various companies to make, use and sell the products covered by the Riggs/Itakura Patents. On August 13, 1999, the City of Hope filed a complaint against us in the Superior Court in Los Angeles County, California, alleging that we owe royalties to the City of Hope in connection with these license agreements, as well as product license agreements that involve the grant of licenses under the Riggs/Itakura Patents. The first trial of this suit began on August 28, 2001. On October 24, 2001, the jury hearing the lawsuit announced that it was unable to reach a verdict and on that basis the Court declared a mistrial. City of Hope requested a retrial, and the retrial began on March 20, 2002. On June 10, 2002, the jury voted to award the City of Hope approximately \$300 million in compensatory damages. On June 24, 2002, the jury voted to award the City of Hope an additional \$200 million in punitive damages. Such amounts were accrued as an expense in the second quarter of 2002 and were included in litigation-related liabilities in the Condensed Consolidated Balance Sheets at June 30, 2003 and December 31, 2002. Genentech filed a notice of appeal of the verdict and damages awards with the California Court of Appeal. The appeal process is ongoing. The amount of cash paid, if any, in connection with the City of Hope matter will depend on the outcome of the appeal.

On June 7, 2000, Chiron Corporation filed a patent infringement suit against us in the U.S. District Court in the Eastern District of California (Sacramento), alleging that the manufacture, use, sale and offer for sale of our Herceptin antibody product infringes Chiron's U.S. Patent No. 6,054,561. This patent was granted on April 25, 2000, and will expire on June 28, 2005, and it relates to certain antibodies that bind to breast cancer cells and/or other cells. Chiron is seeking compensatory damages for the alleged infringement, additional damages (e.g., for willful infringement), and attorneys' fees and costs. On April 22, 2002, the Court issued its decision ("Markman Order") construing certain aspects of the patent claims that are in dispute. On June 25, 2002, the Court issued several decisions regarding summary judgment motions that previously had been filed by Chiron and us. In those decisions, the Court ruled as a matter of law that Herceptin infringes claims 1 to 25 of Chiron's patent, and also ruled as a matter of law in favor of Chiron on some but not all of Genentech's defenses and counterclaims regarding the alleged invalidity and/or unenforceability of the patent. The trial of this suit began on August 6, 2002. Following the first phase of the trial, which related to Genentech's remaining defenses and counterclaims regarding the alleged invalidity of the patent, the jury unanimously found that claims 1 to 25 of Chiron's patent were invalid, and on that basis the Court entered judgment in favor of Genentech. Chiron filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit, and Genentech filed a notice of cross-appeal. The appeal process is ongoing.

On August 12, 2002, the U.S. Patent and Trademark Office (or Patent Office) declared an interference between the Chiron patent involved in the above mentioned lawsuit (U.S. Patent No. 6,054,561) and a patent application exclusively licensed by Genentech from a university relating to anti-HER2 antibodies. An interference proceeding is declared to decide whom first made a particular invention where two or more parties claim the same invention, whether the parties' claims are patentable, and consequently who is or is not entitled to a patent on the invention. In declaring this interference, the Patent Office has determined that there is a substantial question as to whether the inventors of the Chiron patent were first to invent and are entitled to this patent. If the Patent Office were to decide that the inventors of the university's patent application were first to invent and that their claims are patentable, a new patent would be issued to the university and the Chiron patent would be revoked. On October 24,

Page 11

2002, the Patent Office redeclared the interference to include, in addition to the above-referenced Chiron patent and university patent application, a number of patents and patent applications owned by either Chiron or Genentech, including Chiron's U.S. Patent No. 4,753,894 that is also at issue in the separate patent infringement lawsuit described below. The interference proceeding is ongoing.

On March 13, 2001, Chiron filed another patent infringement lawsuit against us in the U.S. District Court in the Eastern District of California, alleging that the manufacture, use, sale and/or offer for sale of our Herceptin antibody product infringes Chiron's U.S. Patent No. 4,753,894. Chiron is seeking compensatory damages for the alleged infringement, additional damages, and attorneys' fees and costs. Genentech filed a motion to dismiss this second lawsuit, which was denied. On November 1, 2002, the parties filed a proposed stipulation to stay all proceedings in this lawsuit until (1) the interference involving U.S. Patent No. 4,753,894 is resolved or (2) two years from entry of the proposed stipulation, whichever is sooner. On or about November 13, 2002, the Court entered the stipulation, staying the proceedings as requested by the parties. This lawsuit is separate from and in addition to the Chiron suit mentioned above.

On July 24, 2002, Green Equity, LLC filed a shareholder derivative lawsuit in the San Francisco Superior Court against Genentech as nominal defendant and against several members of our Board of Directors, and by subsequent amendment of the lawsuit, against several current and former Genentech officers and employees (the "individual defendants"). The lawsuit is based upon the claims made by the City of Hope in the contract dispute referred to above. The complaint alleges that the individual defendants breached the fiduciary duty they owe to Genentech by causing us to withhold royalty payments allegedly due to the City of Hope and to conceal third-party licenses that allegedly should have been disclosed to the City of Hope. The plaintiff seeks unspecified damages, costs, and attorneys' fees. The case was removed to the U.S. District Court in the Northern District of California (San Francisco). Defendants filed motions to dismiss the lawsuit, and on March 6, 2003, the Court issued an order granting in part and denying in part the motions to dismiss. The Court dismissed the Complaint against Genentech and all the individual defendants, except for Jonathan K.C. Knowles. The Court dismissed the Complaint against Knowles with leave to amend. On April 7, 2003, Green Equity, LLC and an additional plaintiff, Warren Jones, filed another amended Complaint against Genentech as nominal defendant and against Dr. Knowles and several other members of our Board of Directors. Defendants again filed motions to dismiss. On June 20, 2003, the Court granted the defendants' motions in their entirety and the entire action was dismissed on the merits against all defendants.

We and Tanox Biosystems, Inc. (or Tanox) are parties to a July 1996 Settlement and Cross-Licensing Agreement relating to the development and manufacture of certain antibody products directed towards immunoglobulin E, including Xolair and Hu-901. On February 20, 2002, Tanox filed an amended demand in an ongoing arbitration proceeding between Genentech and Tanox that is being conducted by the American Arbitration Association in San

Francisco. In its amended demand, Tanox has claimed breach of the July 1996 Agreement, conversion, tortious interference, unjust enrichment, and unfair competition by Genentech, and requests injunctive relief as well as monetary damages "many times in excess of \$100,000,000." On March 14, 2002, Genentech denied all of Tanox's claims, and counterclaimed for breach of contract, theft of trade secrets, misappropriation, breach of confidence, interference with contract, and interference with economic expectancies by Tanox. Genentech requested injunctive relief and monetary damages. On October 16, 2002, Tanox announced that in a dispute between it and Novartis, an arbitration panel ruled that Tanox is not entitled to develop independently the Hu-901 antibody product. The Novartis/Tanox panel also ruled that Tanox is entitled to receive certain know-how from Novartis. Tanox contends in its dispute against Genentech that it is entitled to similar information from Genentech. The effect of the October 16 ruling from the Novartis/Tanox arbitration, if any, on Tanox's claims against Genentech cannot be determined since it has not yet been resolved by the arbitrators in the Tanox/Genentech proceedings. As a general matter, the claims are divided into two categories: (1) compensation for lost rights under agreements with Genentech and Novartis, and (2) additional royalties on future sales. The arbitration began on January 13, 2003 and is ongoing. Tanox closed its case on January 30, 2003 and Genentech closed its case on March 30, 2003. A decision in the arbitration has been delayed and is expected no earlier than July 31, 2003. The outcome of this matter cannot be determined at this time.

On April 11, 2003, MedImmune, Inc. filed a lawsuit against Genentech, City of Hope National Medical Center, and Celltech R & D Ltd. in the U.S. District Court for the Central District of California (Los Angeles). The lawsuit relates to U.S. Patent No. 6,331,415 ("the '415 patent") that is co-owned by Genentech and City of Hope and

under which MedImmune and other companies have been licensed and are paying royalties to Genentech. The lawsuit includes claims for violation of antitrust, patent, and unfair competition laws. MedImmune is seeking to have the '415 patent declared invalid and/or unenforceable, a determination that MedImmune does not owe royalties under the '415 patent on sales of its Synagis® antibody product, an injunction to prevent Genentech from enforcing the '415 patent, an award of actual and exemplary damages, and other relief. Genentech intends to vigorously defend itself against all of the allegations and claims in this lawsuit. An estimate of any potential loss or range of loss cannot be made at this time.

We recorded \$13.4 million in the second quarter and \$26.6 million in the first six months of 2003, for accrued interest and bond costs related to the City of Hope (or COH) trial judgment. In the second quarter and first six months of 2002, we recognized \$518.0 million of litigation-related special charges. These special charges were comprised of the COH trial judgment and certain other litigation-related matters in the second quarter of 2002. In conjunction with the COH trial judgment, in the third quarter of 2002 we posted a \$600.0 million surety bond and as part of this arrangement, we were required to pledge \$630.0 million in cash and investments to secure the bond. The \$630.0 million cash and investments were classified as restricted cash on our Condensed Consolidated Balance Sheets at June 30, 2003 and December 31, 2002. In addition, we accrued \$2.4 million in the first six months of 2003 of royalty expenses related to the COH trial judgment, which was reflected in marketing, general and administrative expenses. We expect that we will continue to incur interest charges on the judgment and service fees on the surety bond each quarter through the process of appealing the COH trial results. These special charges represent our best estimate of the costs for the current resolution of these matters and are included in litigation-related liabilities in the Condensed Consolidated Balance Sheets at June 30, 2003 and December 31, 2002. We developed this estimate in consultation with outside counsel handling our defense in these matters and it is based upon the facts and circumstances of these matters known to us at that time. The amount of our liability for certain of these matters could exceed or be less than the amount of our current estimate, depending on the outcome of these matters. The amount of cash paid, if any, in connection with the City of Hope matter will depend on the outcome of the appeal.

Note 3. RELATIONSHIP WITH ROCHE

Redemption of Our Special Common Stock

On June 30, 1999, we redeemed all of our outstanding Special Common Stock held by stockholders other than Roche Holdings, Inc. (or Roche) with funds deposited by Roche for that purpose. This event, referred to as the "Redemption," caused Roche to own 100% of our common stock on that date. The Redemption was reflected as a purchase of a business which under U.S. generally accepted accounting principles, required push-down accounting to reflect in our financial statements the amount paid for our stock in excess of our net book value plus Roche's transaction costs at June 30, 1999. See Note 4, "Goodwill and Other Intangible Assets," for the amortization of our other intangible assets.

Licensing Agreement

In June 2003, Hoffmann-La Roche, an affiliate of Roche, exercised its option to license from us the rights to market Avastin for all countries outside of the U.S. under its existing licensing agreement with us. As part of its opt-in, Hoffmann-La Roche will pay us \$188.0 million and will pay 75% of all subsequent global development costs related to Avastin. We will receive royalties on all net sales of Avastin in countries outside of the U.S.

Roche's Ability to Maintain Its Percentage Ownership Interest in Our Stock

We expect from time to time to issue additional shares of common stock in connection with our stock option and stock purchase plans, and we may issue additional shares for other purposes. Our affiliation agreement with Roche provides, among other things, that we will establish a stock repurchase program designed to maintain Roche's percentage ownership interest in our common stock. The affiliation agreement provides that we will repurchase a sufficient number of shares pursuant to this program such that, with respect to any issuance of common stock by Genentech in the future, the percentage of Genentech common stock owned by Roche immediately after such issuance will be no lower than Roche's lowest percentage ownership of Genentech common stock at any time after the offering of common stock occurring in July 1999 and prior to the time of such issuance, except that Genentech

may issue shares up to an amount that would cause Roche's lowest percentage ownership to be no more than 2% below the "Minimum Percentage." The Minimum Percentage equals the lowest number of shares of Genentech common stock owned by Roche since the July 1999 offering (to be adjusted in the future for dispositions of shares of Genentech common stock by Roche as well as for stock splits or stock combinations) divided by 509,194,352 (to be adjusted in the future for stock splits or stock combinations), which is the number of shares of Genentech common stock outstanding at the time of the July 1999 offering, as adjusted for the two-for-one splits of Genentech common stock in November 1999 and October 2000. As long as Roche's percentage ownership is greater than 50%, prior to issuing any shares, the affiliation agreement provides that we will repurchase a sufficient number of shares of our common stock such that, immediately after our issuance of shares, Roche's percentage ownership will be greater than 50%. The affiliation agreement also provides that, upon Roche's request, we will repurchase shares of our common stock to increase Roche's ownership to the Minimum Percentage. In addition, Roche will have a continuing option to buy stock from us at prevailing market prices to maintain its percentage ownership interest. On June 30, 2003, Roche's percentage ownership of our common stock was 59.2%.

Note 4. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill represents the difference between the purchase price and the fair value of the net assets when accounted for by the purchase method of accounting arising from the Redemption (see above Note 3, "Relationship With Roche"). The carrying amount of goodwill at June 30, 2003 and December 31, 2002 was \$1,334.2 million. We performed an impairment test of goodwill upon adoption of FAS 142 on January 1, 2002, and an impairment test on September 30, 2002, and found no impairment. We will continue to monitor the carrying value of our goodwill through impairment tests performed at least annually.

The components of our acquisition-related intangible assets arising from the Redemption and push-down accounting (see above Note 3, "Relationship With Roche"), patents and other intangible assets at June 30, 2003 and December 31, 2002, are as follows (in millions):

	June 30, 2003			December 31, 2002		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Developed product technology	\$ 1,194.1	\$ 730.0	\$ 464.1	\$ 1,194.1	\$ 690.4	\$ 503.7
Core technology	443.5	318.9	124.6	443.5	308.0	135.5
Developed license technology	467.5	409.2	58.3	467.5	394.6	72.9
Tradenames	144.0	60.3	83.7	144.0	55.5	88.5
Key distributor relationships	80.0	65.3	14.7	80.0	58.0	22.0
Patents	106.4	40.7	65.7	100.0	36.2	63.8
Other intangible assets	94.0	39.4	54.6	77.3	36.2	41.1
Total	<u>\$ 2,529.5</u>	<u>\$ 1,663.8</u>	<u>\$ 865.7</u>	<u>\$ 2,506.4</u>	<u>\$ 1,578.9</u>	<u>\$ 927.5</u>

Amortization expense of our other intangible assets was \$42.3 million in the second quarter and \$85.3 million in the first six months of 2003, and \$42.3 million in the second quarter and \$84.7 million in the first six months of 2002.

The expected future annual amortization expense of our other intangible assets is as follows (in millions):

For the Year Ending December 31,	Amortization Expense
	\$ 85.4
2003 (remaining six months)	
2004	162.3
2005	139.3
2006	119.4
2007	118.1

2008	116.2
2009-2015	125.0
Total expected future annual amortization	\$ 865.7

Note 5. DERIVATIVE FINANCIAL INSTRUMENTS

We record gains and losses on derivatives related to our equity hedging instruments in "other income, net" in the Condensed Consolidated Statements of Operations. We had no such gains or losses in the second quarter and first six months of 2003 or in the comparable periods of 2002.

At June 30, 2003, net losses on derivative instruments expected to be reclassified from accumulated other comprehensive income to "other income, net" during the next twelve months are \$3.3 million primarily due to the recognition of premiums related to maturing foreign currency exchange options.

Derivative Activity in Accumulated Other Comprehensive Income

The following table summarizes activity in other comprehensive income (or OCI) related to derivatives, net of taxes, held during the second quarters and first six months of 2003 and 2002 (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Changes in fair value of derivatives	\$ 448	\$ 4,205	\$ 1,038	\$ 19,384
Losses (gains) reclassified from OCI to income	634	(2,863)	1,194	(6,441)
Change in unrealized gains on derivatives	\$ 1,082	\$ 1,342	\$ 2,232	\$ 12,943

Note 6. COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) is comprised of net income (loss) and OCI. OCI includes certain changes in stockholders' equity that are excluded from net income (loss). OCI includes changes in fair value of derivatives designated as and effective as hedges and unrealized gains and losses on our available-for-sale securities. The following table summarizes the components of total comprehensive income, net of taxes, during the second quarters and first six months of 2003 and 2002 (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002

Edgar Filing: GENENTECH INC - Form 10-Q

Net income (loss)	\$ 132,345	\$ (213,648)	\$ 283,815	\$ (118,345)
Change in unrealized gains (losses) on securities available-for-sale	21,337	(24,768)	12,747	(81,718)
Change in unrealized gains on derivatives	1,082	1,342	2,232	12,943
Comprehensive income (loss)	<u>\$ 154,764</u>	<u>\$ (237,074)</u>	<u>\$ 298,794</u>	<u>\$ (187,120)</u>

The components of accumulated other comprehensive income, net of taxes, are as follows (in thousands):

	June 30, 2003	December 31, 2002
Unrealized gains on securities available-for-sale	\$ 277,846	\$ 265,099
Unrealized gains on derivatives	5,775	3,543
Accumulated other comprehensive income	<u>\$ 283,621</u>	<u>\$ 268,642</u>

Page 15

Note 7. EARNINGS PER SHARE

The following is a reconciliation of the denominator used in basic and diluted earnings (loss) per share (EPS) computations for the second quarters and first six months of 2003 and 2002 (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Numerator:				
Net income (loss)	<u>\$ 132,345</u>	<u>\$ (213,648)</u>	<u>\$ 283,815</u>	<u>\$ (118,345)</u>
Denominator:				
Weighted-average shares outstanding used for basic earnings (loss) per share	512,909	520,001	512,398	523,361
Effect of dilutive securities:				
Stock options	10,005	-	7,704	-
Weighted-average shares and dilutive stock options used for diluted earnings (loss) per share	<u>522,914</u>	<u>520,001</u>	<u>520,102</u>	<u>523,361</u>

Options to purchase 8,735,449 shares of common stock between \$52.00 and \$95.66 per share were outstanding in the second quarter of 2003, and options to purchase 9,097,041 shares of common stock between \$44.06 and \$95.66 per share were outstanding in the first six months of 2003, but were excluded from the computation of diluted EPS because such options were anti-dilutive in the respective periods. All options to purchase a total of 44,814,455 shares of common stock were outstanding in the second quarter and first six months of 2002, but were excluded from the computation of diluted EPS because such options were anti-dilutive as we had net losses in the respective periods.

Note 8. INVENTORIES

Our inventories are stated at the lower of cost or market. Cost is determined using a weighted-average approach, which approximates the first-in first-out method. If inventory costs exceed expected market value due to obsolescence or unmarketability, reserves are recorded for the difference between the cost and the market value. These reserves are determined based on significant estimates.

Pre-approval inventories, net of reserves, related solely to our Raptiva product candidate, were \$15.4 million at June 30, 2003 and \$4.7 million at December 31, 2002 and were included in work-in-process. In addition, we are under contract to manufacture ENBREL, registered trademark, (etanercept) for Immunex Corporation, a wholly-owned subsidiary of Amgen, and we have not yet received regulatory approval for the manufacturing process. Pre-approval inventories related to ENBREL were \$8.9 million at June 30, 2003 and were included in work-in-process.

Inventories at June 30, 2003 and December 31, 2002 are summarized below (in thousands):

	June 30, 2003	December 31, 2002
Raw materials and supplies	\$ 33,702	\$ 30,181
Work in process	349,419	329,819
Finished goods	39,293	33,542
Total	<u>\$ 422,414</u>	<u>\$ 393,542</u>

Note 9. CAPITAL STOCK

Stock Repurchase Program

Under a stock repurchase program approved by our Board of Directors on October 31, 2001, and extended on August 15, 2002, Genentech was authorized to repurchase up to \$1 billion of our common stock through the period ending June 30, 2003. Purchases by Genentech could be made in the open market or in privately negotiated

transactions from time to time at management's discretion. Genentech could also engage in transactions in other Genentech securities in conjunction with the repurchase program, including derivative securities. Due to the extension of the stock repurchase program in August of 2002, Genentech entered into a new 10b5-1 trading plan on November 13, 2002, to repurchase shares in the open market during those periods each quarter when trading in our stock is restricted under our insider trading policy. This plan covered 2.5 million shares. Under the stock repurchase program, we repurchased approximately 2.2 million shares of our common stock in the second quarter of 2003 at a cost of approximately \$82.1 million and approximately 5.4 million shares of our common stock in the first six months of

2003 at a cost of approximately \$195.3 million. Of those shares repurchased, the number of shares repurchased under Genentech's 10b5-1 insider trading plan were approximately 0.3 million in the second quarter of 2003 and approximately 1.5 million in the first six months of 2003. We repurchased approximately 8.3 million shares of our common stock in the second quarter of 2002 at a cost of approximately \$311.4 million and approximately 12.0 million shares of our common stock during the first six months of 2002 at a cost of approximately \$491.2 million. Of those shares repurchased, the number of shares repurchased under Genentech's prior 10b5-1 insider trading plan were 1.1 million during the second quarter of 2002 and 1.4 million during the first six months of 2002. Under the stock repurchase program, we repurchased approximately 23.8 million shares of our common stock at a cost of approximately \$893.7 million during the period from November 1, 2001, through June 30, 2003. The stock repurchase program expired on June 30, 2003, and has not been extended.

The par value method of accounting is used for common stock repurchases. The excess of the cost of shares acquired over the par value is allocated to additional paid-in capital with the amounts in excess of the estimated original sales price charged to accumulated deficit.

Note 10. TAXES

Our effective tax rate was 32% in the second quarter and 29% in the first six months of 2003 as compared to 42% in the second quarter and 51% in the first six months of 2002. The tax provisions were \$61.1 million in the second quarter and \$117.1 million in the first six months of 2003. The tax benefits were \$156.8 million for the second quarter and \$123.1 million in the first six months of 2002. The tax benefits for the 2002 periods reflect the tax benefits recognized on the litigation-related special charges.

Our effective tax rate increased in the second quarter of 2003 when compared to the first quarter of 2003 primarily as a result of favorable changes in estimates of prior years' items included in the provision for the first quarter.

INDEPENDENT ACCOUNTANTS' REVIEW REPORT

The Board of Directors and Stockholders of Genentech, Inc.

We have reviewed the accompanying condensed consolidated balance sheet of Genentech, Inc. as of June 30, 2003, and the related condensed consolidated statements of operations for the three-month and six-month periods ended June 30, 2003 and 2002 and the condensed consolidated statements of cash flows for the six-month periods ended June 30, 2003 and 2002. These financial statements are the responsibility of Genentech's management.

We conducted our reviews in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data, and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States,

which will be performed for the full year with the objective of expressing an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States.

We have previously audited, in accordance with auditing standards generally accepted in the United States, the consolidated balance sheet of Genentech, Inc. as of December 31, 2002, and the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended (not presented herein) and in our report dated January 14, 2003 (except for the note titled Subsequent Event, as to which the date is February 12, 2003), we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2002, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ERNST & YOUNG LLP

Palo Alto, California
July 8, 2003

Page 18

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

GENENTECH, INC. FINANCIAL REVIEW

OVERVIEW

Genentech is a leading biotechnology company using human genetic information to discover, develop, manufacture and commercialize biotherapeutics for significant unmet medical needs. We manufacture and commercialize 11 biotechnology products listed below and license several additional products to other companies.

- Herceptin (trastuzumab) antibody for the treatment of certain patients with metastatic breast cancer whose tumors overexpress the Human Epidermal growth factor Receptor type 2 (or HER2) protein;
- Rituxan (rituximab) antibody which we market together with IDEC Pharmaceuticals Corporation (or IDEC) for the treatment of patients with relapsed or refractory low-grade or follicular, CD20-positive B-cell non-Hodgkin's lymphoma;

- TNKase (tenecteplase) single-bolus thrombolytic agent for the treatment of acute myocardial infarction (heart attack);
- Activase (alteplase, recombinant) tissue plasminogen activator (or t-PA) for the treatment of acute myocardial infarction, acute ischemic stroke (brain attack) within three hours of the onset of symptoms and acute massive pulmonary embolism (blood clots in the lungs);
- Cathflo Activase (alteplase, recombinant) tissue plasminogen activator approved for the restoration of function to central venous access devices that have become occluded due to a blood clot;
- Nutropin Depot [somatotropin (rDNA origin) for injectable suspension] long-acting growth hormone for the treatment of growth failure associated with pediatric growth hormone deficiency;
- Nutropin AQ [somatotropin (rDNA origin) for injection] liquid formulation growth hormone for the same indications as Nutropin;
- Nutropin [somatotropin (rDNA origin) for injection] human growth hormone for the treatment of growth hormone deficiency in children and adults, growth failure associated with chronic renal insufficiency prior to kidney transplantation and short stature associated with Turner syndrome;
- Protropin (somatrem for injection) growth hormone for the treatment of inadequate endogenous growth hormone secretion, or growth hormone deficiency, in children (manufacture of Protropin has been discontinued but sales will continue through the end of 2003 or until inventory is depleted);
- Pulmozyme (dornase alfa, recombinant) inhalation solution for the treatment of cystic fibrosis; and
- Xolair (omalizumab) for the treatment of moderate-to-severe persistent asthma in adults and adolescents. In June 2003, we received U.S. Food and Drug Administration (or FDA) approval to market Xolair. We began shipping Xolair in July 2003.

We receive royalties on sales of rituximab, Pulmozyme and Herceptin outside of the United States and on sales of human growth hormone, Rituxan, Pulmozyme, Activase and TNKase in Canada from F. Hoffmann-La Roche (or Hoffmann-La Roche). We receive royalties from third parties on sales of growth hormone products within the United States and outside of the United States, on sales of t-PA outside of the United States and Canada, and on sales of tenecteplase outside of the United States, Canada and Japan. We also receive worldwide royalties on additional licensed products that are marketed by other companies.

Redemption of Our Special Common Stock

On June 30, 1999, we redeemed all of our outstanding Special Common Stock held by stockholders other than Roche Holdings, Inc. (or Roche) at a price of \$20.63 per share in cash with funds deposited by Roche for that purpose. We refer to this event as the "Redemption." As a result, on that date, Roche's percentage ownership of our outstanding Common Stock increased from 65% to 100%. Consequently, under accounting principles generally accepted in the United States, we were required to use push-down accounting to reflect in our financial statements the amounts paid for our stock in excess of our net book value. Push-down accounting required us to record \$1,685.7 million of

goodwill and \$1,499.0 million of other intangible assets onto our balance sheet on June 30, 1999. See also below in the "Recurring Charges Related to Redemption" section of Results of Operations and Note 3, "Relationship With Roche -- Redemption of Our Special Common Stock," in the Notes to Condensed Consolidated Financial Statements.

Roche's Ability to Maintain Its Percentage Ownership Interest in Our Stock

We expect from time to time to issue additional shares of common stock in connection with our stock option and stock purchase plans, and we may issue additional shares for other purposes. Our affiliation agreement with Roche provides, among other things, that we establish a stock repurchase program designed to maintain Roche's percentage ownership interest in our common stock. The affiliation agreement provides that we will repurchase a sufficient number of shares pursuant to this program such that, with respect to any issuance of common stock by Genentech in the future, the percentage of Genentech common stock owned by Roche immediately after such issuance will be no lower than Roche's lowest percentage ownership of Genentech common stock at any time after the offering of common stock occurring in July 1999 and prior to the time of such issuance, except that Genentech may issue shares up to an amount that would cause Roche's lowest percentage ownership to be no more than 2% below the "Minimum Percentage." The Minimum Percentage equals the lowest number of shares of Genentech common stock owned by Roche since the July 1999 offering (to be adjusted in the future for dispositions of shares of Genentech common stock by Roche as well as for stock splits or stock combinations) divided by 509,194,352 (to be adjusted in the future for stock splits or stock combinations), which is the number of shares of Genentech common stock outstanding at the time of the July 1999 offering, as adjusted for the two-for-one splits of Genentech common stock in November 1999 and October 2000. As long as Roche's percentage ownership is greater than 50%, prior to issuing any shares, the affiliation agreement provides that we will repurchase a sufficient number of shares of our common stock such that, immediately after our issuance of shares, Roche's percentage ownership will be greater than 50%. The affiliation agreement also provides that, upon Roche's request, we will repurchase shares of our common stock to increase Roche's ownership to the Minimum Percentage. In addition, Roche will have a continuing option to buy stock from us at prevailing market prices to maintain its percentage ownership interest. On June 30, 2003, Roche's percentage ownership of our common stock was 59.2%.

Reclassifications

In the second quarter and first six months of 2003, we made certain classification changes in our Condensed Consolidated Statements of Operations. A new caption titled "other income, net" was added to the Condensed Consolidated Statements of Operations (see below in "Results of Operations -- Other Income, Net" for the composition of this new caption). The "contract and other" caption presented in prior periods was changed to "contract revenues" and the gains from the sale of biotechnology equity securities that were previously included in "contract and other" are now reflected in "other income, net." In addition, write-downs on biotechnology equity securities previously included in "marketing, general and administrative" expenses are now also reflected in the "other income, net," caption.

Certain other reclassifications of prior year amounts have been made to our Condensed Consolidated Statements of Operations and our Condensed Consolidated Balance Sheets to conform with the current year presentation.

Available Information

Our quarterly reports on Form 10-Q, annual reports on Form 10-K and our other filings with the Securities and Exchange Commission, and any amendments to such filings, can be found on our website at

<http://www.gene.com> or can be obtained by contacting our Investor Relations Department at (650) 225-1599 or by sending an e-mail message to investor.relations@gene.com.

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying notes. Actual results could differ materially from those estimates. The following are critical accounting policies important to our financial condition and results of operations presented in the financial statements and require management to make judgments, assumptions and estimates that are inherently uncertain.

Operating Leases

We lease various real properties under operating leases that generally require us to pay taxes, insurance, maintenance and minimum lease payments. Four of our operating leases are commonly referred to as "synthetic leases." A synthetic lease is a form of off-balance sheet financing under which an unrelated third-party funds 100% of the costs for the acquisition and/or construction of the property and leases the asset to a lessee (Genentech), and at least 3% of the third-party funds represent at-risk equity. As the lessee, our synthetic leases have all been treated as operating leases for accounting purposes and financing leases for tax purposes. We periodically review the fair values of the properties we lease in order to determine potential accounting ramifications. Adverse changes in the fair value of the properties we lease and changes in the equity participation of third-parties could affect the classification of these leases from operating to financing for accounting purposes. In addition, our adoption of the Financial Accounting Standards Board's Interpretation No. 46, "Consolidation of Variable Interest Entities," and the related consolidation of our Vacaville synthetic lease effective July 1, 2003, will have a material impact on our financial condition and results of operations. See the "Recent Accounting Pronouncements" and "Leases and Contingencies" sections below for a more complete discussion of our synthetic leases.

Legal Contingencies

We are currently involved in certain legal proceedings as discussed in Note 2, "Leases and Contingencies" in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Form 10-Q. As of June 30, 2003, we have accrued our estimate of the costs for the current resolution of these matters. We developed these estimates in consultation with outside counsel handling our defense in these matters and it is based upon the facts and circumstances of these matters known to us at that time. The amount of our liability for certain of these matters could exceed or be less than the amount of our current estimates, depending on the outcome of these matters.

Revenue Recognition

- We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable, and collectibility is reasonably assured. Allowances are established for estimated uncollectible amounts, product returns and discounts.
- We receive royalties from licensees, which are based on third-party sales of licensed products or technologies. Royalties are recorded as earned in accordance with the contract terms when third-party results can be reliably measured and collectibility is reasonably assured. Royalty estimates are made in advance of amounts collected using historical and forecasted trends.

- Contract revenue for research and development (or R&D) is recorded as earned based on the performance requirements of the contract. Non-refundable license fees for which no further performance obligations exist, and there is no continuing involvement by Genentech, are recognized on the earlier of when the payments are received or when collection is assured.

Revenue from non-refundable upfront license fees and certain guaranteed payments where we continue involvement through development collaboration or an obligation to supply product is recognized ratably over the development period when, at the execution of the agreement, the development period involves

significant risk due to the incomplete stage of the product's development, or over the period of the manufacturing obligation, when, at the execution of the agreement, the product is approved for marketing, or nearly approvable, and development risk has been substantially eliminated. Deferred revenues related to manufacturing obligations are recognized on a straight-line basis over the longer of the contractual term of the manufacturing obligation or the expected period over which we will supply the product.

Revenue associated with performance milestones is recognized based upon the achievement of the milestones, as defined in the respective agreements. Revenue under R&D cost reimbursement contracts is recognized as the related costs are incurred.

Advance payments received in excess of amounts earned are classified as deferred revenue until earned.

See also the "Recent Accounting Pronouncement" section below for a discussion of the Financial Accounting Standards Board (or FASB) Emerging Issues Task Force (or EITF) 00-21, "Revenue Arrangements with Multiple Deliverables," on new accounting guidance for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets.

Research and Development Expenses

Research and development (or R&D) expenses include related salaries, benefits and other headcount related expenses, clinical trial and related clinical manufacturing costs, contract and other outside service fees, and facilities and overhead costs. R&D expenses consist of independent R&D costs and costs associated with collaborative R&D and in-licensing arrangements. In addition, we fund R&D at other companies and research institutions under agreements, which we can generally terminate at will. R&D expenses also include activities such as product registries and investigator sponsored trials. R&D costs, including some upfront fees and milestones paid to collaborators, are expensed as incurred. The timing of upfront fees and milestone payments in the future may cause variability in our future R&D expenses.

Income Taxes

Income tax expense is based on pretax financial accounting income (loss) under the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant

estimates are required in determining our provision (benefit) for income taxes. Various internal and external factors may have favorable or unfavorable effects on our future effective tax rate. These factors include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, future levels of R&D spending, future levels of capital expenditures, and changes in overall levels of pretax earnings. We believe that our reserves for these uncertainties are adequate.

Accounts Receivable Allowances

We prepare estimates for discounts, rebates and sales returns and allowances based primarily on historical trends and experience and changes in customer financial conditions. If actual future results vary, we may need to adjust our estimates, which could have an impact on earnings in the period of the adjustment.

Inventories

Our inventories are stated at the lower of cost or market. Cost is determined using a weighted-average approach, which approximates the first-in first-out method. If inventory costs exceed expected market value due to obsolescence or unmarketability, reserves are recorded for the difference between the cost and the market value. These reserves are determined based on significant estimates.

Inventories consist of currently marketed products, products we manufacture under contract and our product candidates awaiting regulatory approval, which are capitalized based on management's judgment of probable near term commercialization. We may be required to expense previously capitalized costs related to pre-approval

inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by the necessary regulatory bodies.

Marketable Equity Securities and Other

Marketable equity securities and other debt securities are carried at fair value with unrealized gains and losses on securities classified as "available-for-sale" included in accumulated other comprehensive income in stockholders' equity. If the fair value of a security has declined below its carrying value for each trading day for six consecutive months or if the decline is due to a significant adverse event, the impairment is considered to be other-than-temporary. An other-than-temporary decline in fair value of a debt or equity security of a biotechnology company is written down to its estimated fair value with a charge to "other income, net." Other-than-temporary declines in fair value of all other short-term or long-term marketable securities are charged against interest income, included in "other income, net." Some of the factors we consider in determining whether a significant adverse event has occurred with an issuer include, among other things, unfavorable clinical trial results and the diminished prospect for new products, a denial of a product approval by a regulatory body, the termination of a major collaborative relationship and the liquidity position and financing activities of the issuer. The determination of whether a decline in fair value is other-than-temporary requires significant judgment, and can have a material impact on our financial results.

Nonmarketable Equity Securities

Nonmarketable equity securities are carried at cost. We periodically monitor the liquidity position and financing activities of the respective issuers to determine if impairment write-downs are necessary. In the event that

impairment write-downs are recorded and subsequently recovered upon the sale of the related security, our financial results will be favorably impacted. We record impairments in "other income, net."

RESULTS OF OPERATIONS

(dollars in millions, except per share amounts)

This discussion of our Results of Operations contains forward-looking statements regarding the costs related to the completion of in-process projects. Actual results could differ materially. For a discussion of the risks and uncertainties associated with the costs related to the completion of in-process projects see "The Successful Development of Biotherapeutics is Highly Uncertain," "We May Be Unable to Obtain or Maintain Regulatory Approvals for Our Products," "Difficulties or Delays in Product Manufacturing Could Harm Our Business," "Protecting Our Proprietary Rights Is Difficult and Costly" and "We May Be Unable to Retain Skilled Personnel and Maintain Key Relationships" sections of "Forward-Looking Information and Cautionary Factors That May Affect Future Results" below.

	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Total operating revenues	\$ 799.7	\$ 622.3	29 %	\$ 1,549.4	\$ 1,190.3	30 %

Total operating revenues increased 29% in the second quarter and 30% in the first six months of 2003 from the comparable periods in 2002. These increases were due to higher product sales, royalty income and contract revenues. These increases are further discussed below.

Product Sales	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Rituxan	\$ 363.4	\$ 274.9	32 %	\$ 704.4	\$ 522.5	35 %
Herceptin	109.1	95.1	15	202.8	181.9	11
Growth Hormone	81.6	75.3	8	158.3	142.9	11
Thrombolytics	47.6	43.1	10	95.1	85.9	11
Pulmozyme	42.6	35.1	21	82.2	66.9	23
Total product sales	\$ 644.3	\$ 523.5	23 %	\$ 1,242.8	\$ 1,000.1	24 %

Total Product Sales

Total net product sales increased 23% in the second quarter and 24% in the first six months of 2003 from the comparable periods in 2002 due to higher sales across all products, in particular Rituxan. Increased sales volume

accounted for a 20% increase, or \$105.1 million, in the second quarter of 2003 and a 20% increase, or \$201.3 million, in the first six months of 2003, and was, for both periods, primarily attributable to Rituxan. Higher sales prices primarily for our Rituxan, Herceptin and growth hormone products accounted for the remainder of the increase in both periods.

Rituxan

Net sales of Rituxan increased 32% in the second quarter and 35% in the first six months of 2003 from the comparable periods in 2002. These increases were primarily due to increased use of the product for the treatment of B-cell non-Hodgkin's lymphoma in indolent and aggressive non-Hodgkin's lymphoma (NHL), as well as chronic lymphocytic leukemia (CLL), used in both monotherapy and combination therapy settings. The current approved label indication is for relapsed, indolent or low grade NHL. Additionally, in early 2003, the National Comprehensive Cancer Network (or NCCN) issued guidelines that included the use of Rituxan in the relapsed aggressive NHL setting. These increases were also due to, a lesser extent, a price increase.

Herceptin

Net sales of Herceptin increased 15% in the second quarter and 11% in the first six months of 2003 from the comparable periods in 2002. These increases were due to penetration in first-line use in the metastatic breast cancer market and a longer average treatment duration. These increases were also due to, a lesser extent, a price increase. These increases were partially offset by a 20% decline in the second quarter and a 54% decline in the first six months of 2003 in ex-U.S. Herceptin sales from the comparable periods in 2002. In late September 2002, Hoffmann-La Roche received approval from the European Committee for Proprietary Medicinal Products to manufacture Herceptin at its Penzberg, Germany facility. The Penzberg facility will become the primary site for the manufacture of Herceptin to supply ex-U.S. territories. As a result, we expect our ex-U.S. sales of Herceptin to Hoffmann-La Roche to continue to decline during the remainder of 2003. However, we will continue to receive royalties from their ex-U.S. sales of Herceptin.

Growth Hormone

Combined net sales of our four growth hormone products, Nutropin Depot, Nutropin AQ, Nutropin, and Protropin, increased 8% in the second quarter and 11% in the first six months of 2003 from the comparable periods in 2002. These increases were attributable to a price increase and continued strong demand for the products. The continued strong demand reflects our focus on new patient starts using our Nutropin AQ Pen (which is a new delivery system for Nutropin AQ and was launched in July 2002), continued growth in the adult patient market, higher dosing during puberty and an incremental increase in the length of therapy.

Thrombolytics

Combined net sales of our three thrombolytic products, Activase, TNKase and Cathflo Activase, increased 10% in the second quarter and 11% in the first six months of 2003 from the comparable periods in 2002. These increases were primarily due to higher sales of Cathflo Activase for catheter clearance as a result of increased acceptance and use of the product and to a lesser extent, price increases on our thrombolytic products. Additionally, modest increases in Activase usage for acute ischemic stroke are being observed. The total thrombolytic market has been flat compared to last year, reflecting growth in the peripheral markets, including catheter clearance and stroke, offset by the continued decline in the overall size of the thrombolytic market for acute myocardial infarction (or AMI) due to increasing use of mechanical reperfusion, early intervention with other therapies in the treatment of AMI, and preventative therapies.

Pulmozyme

Net sales of Pulmozyme increased 21% in the second quarter and 23% in the first six months of 2003 from the comparable periods in 2002. These increases primarily reflect an increased focus on aggressive treatment of cystic fibrosis early in the course of the disease. The increase in the first six months was also due to, a lesser extent, a price increase.

Royalties and Contract Revenues	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Royalties	\$ 122.8	\$ 85.5	44 %	\$ 236.1	\$ 167.4	41 %
Contract revenues	32.6	13.3	145	70.5	22.8	209

Royalties

Royalty income increased 44% in the second quarter and 41% in the first six months of 2003 from the comparable periods in 2002. These increases were due to higher third-party sales by various licensees, primarily Hoffmann-La Roche on higher international sales volume of our Herceptin and Rituxan products, coupled with gains on foreign currency exchange rates related to such sales.

Contract Revenues

Contract revenues increased 145% in the second quarter of 2003 compared to the same period in 2002. This increase was primarily due to higher revenues from collaborators for amounts earned on development activities related to Avastin, Tarceva and Raptiva, and from new licensing arrangements. Contract revenues increased 209% in the first six months of 2003 from the comparable period in 2002. This increase was primarily due to a milestone payment from a third-party collaborator, new licensing arrangements and higher revenues from collaborators.

Costs and Expenses	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Cost of sales	\$ 123.4	\$ 106.9	15 %	\$ 238.2	\$ 209.3	14 %
Research and development	180.2	147.9	22	337.6	294.6	15
Marketing, general and administrative	184.3	125.7	47	321.5	241.1	33
Collaboration profit sharing	107.3	84.1	28	203.9	156.2	31
Recurring charges related to redemption	38.6	38.9	(1)	77.2	77.8	(1)
Special charges: Litigation-related	13.4	518.0	(97)	26.7	518.0	(95)
Total costs and expenses	\$ 647.2	\$ 1,021.5	(37) %	\$ 1,205.1	\$ 1,497.0	(20) %

COS as a % of product sales	19 %	20 %	19 %	21 %
R&D as a % of operating revenues	23	24	22	25
MG&A as a % of operating revenues	23	20	21	20

Cost of Sales

Cost of sales as a percentage of product sales was 19% in the second quarter and first six months of 2003, a decrease from 20% in the second quarter and 21% in the first six months of 2002. These decreases primarily reflect lower production costs for products sold in 2003.

As mentioned above, the Penzberg facility will become the primary site for the manufacture of Herceptin to supply ex-U.S. territories. Accordingly, if our ex-U.S. Herceptin sales decline in late 2003 as expected, our cost as a percentage of sales is also expected to decline due to lower gross margins generated by the ex-U.S. Herceptin sales.

Research and Development

R&D expenses increased 22% in the second quarter and 15% in the first six months of 2003 from the comparable periods in 2002. These increases were largely due to higher spending by us and our collaborators on late-stage clinical development of products, including Lucentis and Tarceva, increased Phase IV and investigator sponsored trials and increased headcount and related expenses in support of research activities. These increases were offset in part by lower in-licensing expenses during the first six months of 2003.

The major components of R&D expenses for the three- and six-month periods ended June 30, 2003 and 2002 were as follows (in millions):

Research and Development	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Research	\$ 37.7	\$ 32.7	15 %	\$ 74.5	\$ 62.7	19 %
Development	133.2	104.3	28	248.1	212.2	17
In-licensing	9.3	10.9	(15)	15.0	19.7	(24)
Total	\$ 180.2	\$ 147.9	22 %	\$ 337.6	\$ 294.6	15 %

Marketing, General and Administrative

Overall marketing, general and administrative (or MG&A) expenses increased 47% in the second quarter of 2003 over the same period in 2002. This increase was primarily due to: (i) a \$19.7 million increase in marketing and promotional programs and headcount growth in support of commercial and pipeline products, including pre-launch

activities related to Xolair, (ii) a \$15.3 million increase in corporate functional and other expenses, (iii) a \$12.6 million increase related to headcount growth and increased commercial training programs in support of all products, and (iv) an \$11.0 million increase in royalty expenses.

MG&A expense increased 33% in the first six months of 2003 from the comparable period in 2002. This increase was primarily due to: (i) a \$33.4 million increase in marketing and promotional programs and headcount growth in support of commercial and pipeline products, including pre-launch activities related to Xolair, (ii) a \$20.2 million increase related to headcount growth and increased commercial training programs in support of all products, (iii) an \$19.2 million increase in royalty expenses, and (iv) a \$7.6 million increase in corporate functional and other expenses, partially offset by lower fixed asset disposals.

Collaboration Profit Sharing

Collaboration profit sharing increased 28% in the second quarter and 31% in the first six months of 2003 from the comparable periods in 2002. These increases were primarily due to increased profit sharing with IDEC resulting from higher Rituxan sales.

Recurring Charges Related to Redemption

We began recording recurring charges related to the Redemption and push-down accounting in the third quarter of 1999. The charges in the second quarter and first six months of 2003 were comparable to the second quarter and first six months of 2002, and were comprised of the amortization of other intangible assets in all periods presented.

Special Charges: Litigation-Related

We recorded \$13.4 million in the second quarter and \$26.7 million in the first six months of 2003, for accrued interest and bond costs related to the City of Hope (or COH) trial judgment. In the second quarter and first six months of 2002, we recognized \$518.0 million of litigation-related special charges. These special charges were comprised of the COH trial judgment and certain other litigation-related matters in the second quarter of 2002. We expect that we will continue to incur interest charges on the COH trial judgment and service fees on a related \$600.0 million surety bond each quarter through the process of appealing the COH trial results. These special charges

represent our best estimate of the costs for the current resolution of these matters and are included in litigation-related liabilities in the Condensed Consolidated Balance Sheets at June 30, 2003 and December 31, 2002. We developed this estimate in consultation with outside counsel handling our defense in these matters and it is based upon the facts and circumstances of these matters known to us at that time. The amount of our liability for certain of these matters could exceed or be less than the amount of our current estimate, depending on the outcome of these matters. The amount of cash paid, if any, in connection with the COH matter will depend on the outcome of the appeal. See Note 2, "Leases and Contingencies," in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further information regarding our litigations.

Other Income, Net

Edgar Filing: GENENTECH INC - Form 10-Q

As part of our strategic alliance efforts, we invest in debt and equity securities of certain biotechnology companies with which we have or have had collaborative agreements. "Other income, net" includes realized gains and losses from the sale of certain of these biotechnology equity securities and write-downs for other-than-temporary declines in the fair value of certain of these biotechnology debt and equity securities. In addition, "other income, net," includes interest income and interest expense, net of amounts capitalized.

Other Income, Net	Three Months Ended June 30,			Six Months Ended June 30,		
	2003	2002	% Change	2003	2002	% Change
Gains on sales of biotechnology equity securities	\$ 19.7	\$ -	- %	\$ 20.2	\$ 17.2	17 %
Write-downs of biotechnology debt and equity securities	-	(1.2)	-	(3.7)	(9.4)	61
Interest income	21.2	30.0	(29)	40.1	58.2	(31)
Interest expense	-	-	-	-	(0.8)	-
Total other income, net	\$ 40.9	\$ 28.8	42 %	\$ 56.6	\$ 65.2	(13) %

"Other income, net," increased 42% in the second quarter and decreased 13% in the first six months of 2003 from the comparable periods in 2002. The increase in the second quarter of 2003 was primarily due to higher gains on sales of biotechnology securities, partially offset by lower interest income resulting from lower investment portfolio yields. The decrease in the first six months of 2003 as compared to 2002 was mostly due to lower interest income resulting from lower investment portfolio yields, partially offset by lower write-downs of biotechnology equity securities. Depending on market conditions, we may determine that in future periods certain of our other unhedged biotechnology marketable equity securities are impaired, which could result in additional write-downs of those equity securities.

Income (Loss) Before Taxes, Income Tax Provision (Benefit), Net Income (Loss) and Earnings (Loss) Per Share	Three Months Ended June 30,		Six Months Ended June 30,	
	2003	2002	2003	2002
Income (loss) before taxes	\$ 193.4	\$ (370.4)	\$ 400.9	\$ (241.5)
Income tax provision (benefit)	61.1	(156.8)	117.1	(123.1)
Net income (loss)	132.3	(213.6)	283.8	(118.4)
Earnings (loss) per share:				
Basic	0.26	(0.41)	0.55	(0.23)
Diluted	0.25	(0.41)	0.55	(0.23)

Income Tax Provision (Benefit)

Our effective tax rate was 32% in the second quarter and 29% in the first six months of 2003 as compared to 42% in the second quarter and 51% in the first six months of 2002. The tax provisions were \$61.1 million in the second quarter and \$117.1 million in the first six months of 2003. The tax benefits were \$156.8 million for the second quarter and \$123.1 million in the first six months of 2002. The tax benefits for the 2002 periods reflect the tax benefits recognized on the litigation-related special charges.

Page 27

Our effective tax rate increased in the second quarter of 2003 when compared to the first quarter of 2003 primarily as a result of favorable changes in estimates of prior years' items included in the provision for the first quarter. We anticipate that our effective tax rate for the entire year 2003 may be slightly lower than that recorded during the second quarter of 2003. Various factors may have favorable or unfavorable effects on our effective tax rate during the remainder of 2003 and in subsequent years. These factors include, but are not limited to, interpretations of existing tax laws, changes in tax laws and rates, future levels of R&D spending, future levels of capital expenditures, and changes in overall levels of pretax earnings.

Net Income and Earnings Per Share

Net income and diluted earnings per share in the second quarter and first six months of 2003 increased from the comparable periods in 2002 primarily as a result of the litigation-related special charges in the second quarter of 2002 and higher operating revenues in 2003, driven mostly by higher product sales, offset in part by higher operating expenses in 2003.

In-Process Research and Development

At June 30, 1999, the Redemption date, we determined that the acquired in-process technology was not technologically feasible and that the in-process technology had no future alternative uses. As a result, \$500.5 million of in-process research and development (or IPR&D) related to Roche's 1990 through 1997 purchases of our common stock was charged to additional paid-in capital, and \$752.5 million of IPR&D related to the Redemption was charged to operations at June 30, 1999.

Except as otherwise noted below, there have been no significant changes to the projects since December 31, 2002. We do not track all costs associated with research and development on a project-by-project basis. Therefore, we believe a calculation of cost incurred as a percentage of total incurred project cost as of the FDA approval is not possible. We estimate, however, that the research and development expenditures that will be required to complete the in-process projects will total at least \$350.0 million, as compared to \$700.0 million as of the Redemption date. This estimate reflects costs incurred since the Redemption date, discontinued projects, and decreases in cost to complete estimates for other projects, partially offset by an increase in certain cost estimates related to early stage projects and changes in expected completion dates.

The following are significant changes that occurred during the first six months of 2003, to the projects included in the IPR&D charge at the Redemption:

- Xolair (omalizumab) - We announced on June 20, 2003, that the U.S. Food and Drug Administration has approved Xolair™ (omalizumab) for the treatment of moderate-to-severe persistent asthma in adults and adolescents.

- Herceptin antibody - Phase III program studying Herceptin as an adjuvant therapy for breast cancer may take longer to complete than originally anticipated.
- Lucentis (ranibizumab) - We have initiated two Phase III studies for patients with the wet form of age-related macular degeneration.
- Raptiva (efalizumab) - We announced on May 12, 2003, in co-development with XOMA Ltd., the decision to terminate Phase II testing of Raptiva™ (efalizumab) in patients with moderate-to-severe rheumatoid arthritis.
- MLN02 antibody - Results announced on May 21, 2003, of a Phase II trial of MLN02 in patients with ulcerative colitis showed statistically significant improvements in the clinical remission rates of patients treated with MLN02 compared to placebo, the trial's primary endpoint. We are co-developing MLN02 with Millenium Pharmaceuticals.

Page 28

- Avastin (bevacizumab) - We announced on May 19, 2003, that a Phase III study of Avastin™ (bevacizumab) plus chemotherapy in previously untreated metastatic colorectal cancer patients met its primary endpoint of improving overall survival. We announced on June 26, 2003, the U.S. Food and Drug Administration has designated Avastin as a Fast Track development program for the treatment of previously untreated first line metastatic colorectal cancer patients.

Recent Accounting Pronouncements

In November 2002, the EITF of the FASB issued EITF 00-21, "Revenue Arrangements with Multiple Deliverables," which addresses certain aspects of the accounting for arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. Under EITF 00-21, revenue arrangements with multiple deliverables should be divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration should be allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria should be considered separately for each of the separate units of accounting. EITF 00-21 is effective for revenue arrangements we enter into after June 30, 2003. We are currently evaluating the impact of EITF 00-21 on revenue arrangements we enter into in the future, which will need to comply with EITF 00-21.

In November 2002, the FASB issued Interpretation No. 45 (or FIN 45), "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN 45 elaborates on the existing disclosure requirements for most guarantees, including residual value guarantees issued in conjunction with operating lease agreements. It also clarifies that at the time a company issues a guarantee, the company must recognize an initial liability for the fair value of the obligation it assumes under that guarantee and must disclose that information in its interim and annual financial statements. The initial recognition and measurement provisions apply on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. Our adoption of FIN 45 did not have a material impact on our results of operations and financial position. See below in "Leases and Contingencies" for a discussion of our exposures related to our agreement with Serono S.A. and our synthetic leases and the related residual value guarantees.

In January 2003, the FASB issued Interpretation No. 46 (or FIN 46), "Consolidation of Variable Interest Entities." FIN 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. A variable interest entity is a corporation, partnership, trust, or any other legal structures used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A variable interest entity often holds financial assets, including loans or receivables, real estate or other property. A variable interest entity may be essentially passive or it may engage in research and development or other activities on behalf of another entity. The consolidation requirements of FIN 46 apply to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply to all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. See below in "Leases and Contingencies" for a discussion of our synthetic leases and the expanded disclosures required by FIN 46.

In December 2002, the FASB issued Statement No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." FAS 148 amends FAS 123 "Accounting for Stock-Based Compensation" to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The additional disclosure requirements of FAS 148 are effective for fiscal years ending after December 15, 2002. We have elected to continue to follow the intrinsic value method of accounting as prescribed by Accounting Principles Board Opinion No. 25 (or APB 25), "Accounting for Stock Issued to Employees," to account for employee stock options. Under APB 25, no compensation expense is recognized unless the exercise price of our employee stock options is less than the market

price of the underlying stock on the date of grant. We have not recorded such expenses in the periods presented because we grant options at the fair market value of the underlying stock on the date of grant. See Note 1, "Summary of Significant Accounting Policies" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for the required disclosures under FAS 148.

FINANCIAL CONDITION

Liquidity and Capital Resources

(in millions)	June 30, 2003	December 31, 2002
Cash and cash equivalents, short-term investments and long-term marketable securities and other	\$ 2,001.7	\$ 1,601.9
Working capital	1,953.6	1,436.1

We used cash generated from operations, income from investments and proceeds from stock issuances to fund operations, purchase marketable securities, make capital and equity investments and to make stock repurchases during the first six months of 2003 and 2002, and to redeem our convertible subordinated debentures in the first quarter of 2002.

Under a stock repurchase program approved by our Board of Directors on October 31, 2001, and extended on August 15, 2002, Genentech was authorized to repurchase up to \$1 billion of our common stock through the period ended June 30, 2003. Purchases by Genentech could be made in the open market or in privately negotiated transactions from time to time at management's discretion. Genentech could also engage in transactions in other Genentech securities in conjunction with the repurchase program, including derivative securities. Due to the extension of the stock repurchase program in August of 2002, Genentech entered into a new 10b5-1 trading plan on November 13, 2002, to repurchase shares in the open market during those periods each quarter when trading in our stock is restricted under our insider trading policy. This plan covered 2.5 million shares. Under the stock repurchase program, we repurchased 2.2 million shares of our common stock in the second quarter of 2003 at a cost of \$82.1 million and 5.4 million shares of our common stock in the first six months of 2003 at a cost of \$195.3 million. Of those shares repurchased, the number of shares repurchased under Genentech's 10b5-1 insider trading plan was 0.3 million in the second quarter of 2003 and 1.5 million in the first six months of 2003. We repurchased 8.3 million shares of our common stock in the second quarter of 2002 at a cost of \$311.4 million and 12.0 million shares of our common stock during the first six months of 2002 at a cost of \$491.2 million. Of those shares repurchased, the number of shares repurchased under Genentech's prior 10b5-1 insider trading plan was 1.1 million during the second quarter of 2002 and 1.4 million during the first six months of 2002. Under the stock repurchase program, we repurchased 23.8 million shares of our common stock at a cost of \$893.7 million during the period from November 1, 2001, through June 30, 2003. The stock repurchase program expired on June 30, 2003 and has not been extended.

Capital expenditures of \$140.1 million in the first six months of 2003 decreased from the \$163.8 million in the comparable period of 2002 primarily due to higher spending in 2002 for land and building purchases.

We believe that our cash, cash equivalents and short-term investments, together with funds provided by operations and leasing arrangements, will be sufficient to meet our foreseeable future operating cash requirements. In addition, we believe we could access additional funds from the debt and, under certain circumstances, capital markets. See above for a discussion of our leasing arrangements. See "Our Affiliation Agreement With Roche Could Adversely Affect Our Cash Position" section below and Note 2, "Leases and Contingencies," in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for factors that could negatively affect our cash position.

LEASES AND CONTINGENCIES

Leases

We lease various real properties under operating leases that generally require us to pay taxes, insurance, maintenance and minimum lease payments. Some of our leases have options to renew. Four of our operating leases are commonly referred to as synthetic leases. A synthetic lease represents a form of off-balance sheet financing under which an unrelated third-party funds 100% of the costs of the acquisition and/or construction of the property

and leases the asset to a lessee (Genentech), and at least 3% of the third-party funds represent at-risk equity. As the lessee, our synthetic leases are treated as operating leases for accounting purposes and as financing leases for tax purposes. (See also below regarding FIN 46). Under our synthetic lease structures, upon termination or expiration, at our option, we must either purchase the property from the lessor at a predetermined amount that does not constitute a purchase at less than fair market value, sell the real property to a third-party, or renew the lease arrangement. If the property is sold to a third-party at an amount less than the amount financed by the lessor, we have agreed under

residual value guarantees to pay the lessor up to an agreed upon percentage of the amount financed by the lessor.

Three of our four synthetic leases were entered into with BNP Paribas Leasing Corporation (or BNP), which leases directly to us various buildings that we occupy in South San Francisco, California. Under certain of these leases, we are required to maintain cash collateral of \$56.6 million, which we have included in our Condensed Consolidated Balance Sheets as restricted cash.

The most significant of our synthetic leases relates to our manufacturing facility located in Vacaville, California. In November 2001, we completed a synthetic lease transaction for this facility, which had previously been leased to us under a predecessor synthetic lease. This new synthetic lease is structured differently from our other synthetic leases. As the lessee, we lease the property from an unrelated special purpose trust (owner/lessor) under an operating lease agreement for five years ending November 2006. Third-party financing is provided in the form of a 3% at-risk equity participation from investors and 97% debt commitment. Investors' equity contributions were equal to or greater than 3% of the fair value of the property at the lease's inception and are required to remain so for the term of the lease. A bankruptcy-remote, special purpose corporation (SPC) was formed to fund the debt portion through the issuance of commercial paper notes. The SPC lends the proceeds from the commercial paper to the owner/lessor, who issues promissory notes to the SPC. The SPC loans mature in November 2006. The SPC promissory notes are supported by a credit facility provided by financing institutions and draws are generally available under that credit facility to repay the SPC's commercial paper. The collateral for the SPC loans includes the leased property, and an interest in the residual value guarantee provided by us. As the lessee, at any time during the lease term, we have the option to purchase the property at an amount that does not constitute a purchase at less than fair market value. Our off-balance sheet contingent liability under the residual value guarantees is summarized in the table below.

Under all the synthetic leases, Genentech, as the lessee, is also required to maintain certain pre-defined financial ratios and is limited to the amount of debt it can assume. In addition, no Genentech officers or employees have any financial interest with regards to these synthetic lease arrangements or with any of the special purpose entities used in these arrangements. In the event of a default, the maximum amount payable under the residual value guarantee would equal 100% of the amount financed by the lessor, and our obligation to purchase the leased properties or pay the related residual value guarantees could be accelerated. We believed at the inception of the leases and continue to believe that the occurrence of any event of default that could trigger our purchase obligation is remote.

Future minimum lease payments under operating leases, exclusive of the residual value guarantees, executory costs and sublease income, at December 31, 2002, are as follows (in millions). These minimum lease payments were computed based on interest rates current at that time, which are subject to fluctuations in certain market-based interest rates:

	2003	2004	2005	2006	2007	Thereafter	Total
Synthetic leases	\$ 9.6	\$ 9.4	\$ 8.8	\$ 8.8	\$ 1.3	\$ -	\$ 37.9
Other operating leases	4.8	3.3	3.1	2.6	2.4	5.2	21.4
Total	\$ 14.4	\$ 12.7	\$ 11.9	\$ 11.4	\$ 3.7	\$ 5.2	\$ 59.3

Edgar Filing: GENENTECH INC - Form 10-Q

The following summarizes the approximate assumed carrying values of the leased properties as of December 31, 2002, which represents the initial fair values of the facilities at the inception of the related leases, less assumed depreciation through June 30, 2003, and residual value guarantee amounts for our synthetic leases (in millions):

	Approximate Initial Fair Value of Leased Property	Estimated Accumulated Depreciation	Estimated Carrying Value	Lease Expiration	Maximum Residual Value Guarantee
South San Francisco Lease 1	\$ 56.6	\$ 21.4	\$ 35.2	07/2004	\$ 48.1
South San Francisco Lease 2	152.0	29.2	122.8	06/2007	129.2
South San Francisco Lease 3	25.0	4.9	20.1	01/2004	21.3
Vacaville Lease	425.0	66.0	359.0	11/2006	371.8
Total	\$ 658.6	\$ 121.5	\$ 537.1		\$ 570.4

We believe that there have been no impairments in the fair value or use of the properties that we lease under synthetic leases wherein we believe that we would be required to pay amounts under any of the residual value guarantees. We will continue to assess the fair values of the underlying properties and the use of the properties for impairment at least annually.

The maximum exposure to loss on our synthetic leases include (i) residual value guarantee payments as shown above, (ii) certain tax indemnifications in the event the third-parties are obligated for certain federal, state or local taxes as a result of their participation in the transaction, and (iii) indemnification for various losses, costs and expenses incurred by the third-party participants as a result of their ownership of the leased property or participation in the transaction, and as a result of the environmental condition of the property. The additional taxes, losses and expenses as described in (ii) and (iii) are contingent upon the existence of certain conditions and, therefore, would not be quantifiable at this time. However, we do not expect these additional taxes, losses and expenses to be material. In the case of Lease 1, we have pledged cash collateral of \$56.6 million as a source of payment for Genentech's obligation for the residual value guarantee payments and other amounts we owe under the lease.

Under FIN 46, synthetic leasing structures that qualify as variable interest entities are required to be consolidated by the primary beneficiary. We have determined that the leasing structure used in the Vacaville Lease qualifies as a variable interest entity under FIN 46. Accordingly, with respect to our Vacaville Lease, we have determined that, effective July 1, 2003, we will need to consolidate assets of approximately \$359.0 million, net of accumulated depreciation, liabilities of approximately \$412.3 million and noncontrolling interests of approximately \$12.7 million, and we expect to record a charge of approximately \$39.6 million, net of tax, as a cumulative effect of an accounting change on July 1, 2003. We are in the process of finalizing our assessment of the related fair values, which may vary from the actual fair values we record upon adoption. With regard to BNP Leases 1, 2 and 3, we have determined that these leases do not qualify as variable interest entities and accordingly, we will not be required to consolidate the related assets and liabilities under FIN 46 on July 1, 2003.

Contingencies

In August 2002, we entered into an agreement with Serono S.A. to market Raptiva internationally outside the United States, Japan, and certain other Asian countries. In February 2003, we amended the agreement with Serono to expand Serono's marketing rights to include certain additional Asian countries other than Japan. Development and marketing rights in the United States remain with us and our U.S. collaborator, XOMA (US) LLC, and we retain exclusive marketing rights in Japan. Under the agreement, we and Serono may collaborate on co-developing additional indications of Raptiva and will share certain global development costs. In addition, we have a supply agreement with Serono, under which we could have a loss exposure up to a maximum of \$10.0 million.

We are a party to various legal proceedings, including patent infringement litigation relating to our antibody products, and licensing and contract disputes, and other matters. See Note 2, "Leases and Contingencies" in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Form 10-Q for further information.

RELATED PARTY TRANSACTIONS

We enter into transactions with Roche, Hoffmann-La Roche and its affiliates in the ordinary course of business. In June 2003, Hoffmann-La Roche exercised its option to license from us the rights to market Avastin for all countries outside of the U.S. under its existing licensing agreement with us. As part of its opt-in, Hoffmann-La Roche will pay us \$188.0 million and will pay 75% of all subsequent global development costs related to Avastin. We will receive royalties on all net sales of Avastin in countries outside of the U.S. Contract revenue from Hoffmann-La Roche, including amounts earned related to ongoing development activities after the option exercise date, totaled \$7.5 million in the second quarter and \$9.6 million in the first six months of 2003 compared to \$3.3 million in the second quarter and \$5.4 million in the first six months of 2002. All other revenues from Roche, Hoffmann-La Roche and their affiliates, principally royalties and product sales, totaled \$93.4 million in the second quarter and \$169.6 million in the first six months of 2003, and \$64.7 million in the second quarter and \$111.9 million in the first six months of 2002.

We understand that Novartis AG (or Novartis) holds approximately 32.7% of the outstanding voting shares of Roche Holding Ltd. As a result of this ownership, Novartis is deemed to have an indirect beneficial ownership interest under FAS 57 "Related Party Disclosures" of more than 10% of Genentech's voting stock. In June 2003, we entered into an agreement with Novartis Ophthalmics, an affiliate of Novartis AG, under which Novartis Ophthalmics will receive an exclusive license to develop and market Lucentis outside of North America for indications related to diseases of the eye. As part of this agreement, we received from Novartis Ophthalmics an upfront fee of \$40.0 million in July 2003, and may receive additional payments for achievement of clinical development and product approval milestones and as well as royalties on net sales of Lucentis products outside North America. During 2000, we entered into an arrangement with Novartis, whereby Novartis was required to fund a portion of the cost of our Xolair inventory until the FDA approved the product for marketing. This amount was required to be returned to Novartis upon the earlier of regulatory approval of Xolair in the U.S. or the European Union, and was recorded in other accrued liabilities in our financial statements. The amount payable to Novartis was \$37.8 million at June 30, 2003 and December 31, 2002. In June 2003, we received FDA approval to market Xolair. As a result, the \$37.8 million was returned to Novartis in July 2003. Contract revenue from Novartis, including amounts recognized under new licensing arrangements entered into in the second quarter of 2003 and amounts earned related to ongoing development activities was \$10.9 million in the second quarter and \$11.1 million in the first six months of 2003, and was \$1.6 million in the second quarter and \$3.2 million in the first six months of 2002.

STOCK OPTIONS

Option Program Description

Our stock option program is a broad-based, long-term retention program that is intended to attract and retain talented employees and to align stockholder and employee interests. Our program primarily consists of our amended and restated 1999 Stock Plan (the "Plan"), a broad-based plan under which stock options are granted to employees, directors and other service providers. Substantially all of our employees participate in our stock option program. In the past, we granted options under our amended and restated 1996 Stock Option/Stock Incentive Plan, our amended and restated 1994 Stock Option Plan and our amended and restated 1990 Stock Option/Stock Incentive Plan. Although we no longer grant options under these plans, exercisable options granted under these plans are still outstanding.

All stock option grants are made at the fair market value of the underlying stock at the date of grant after a review by, and with the approval of, the Compensation Committee of the Board of Directors. See "The Compensation Committee Report" appearing in our 2003 Proxy Statement on file with the Securities and Exchange Commission for further information concerning the policies and procedures of the Compensation Committee regarding the use of stock options.

Page 33

General Option Information

Summary of Option Activity

(Shares in thousands)

	Shares Available for Grant	Options Outstanding	
		Number of Shares	Weighted Average Exercise Price
December 31, 2001	14,509	46,640	\$ 41.06
Grants	(12,655)	12,655	28.98
Exercises	-	(1,673)	23.43
Cancellations ⁽¹⁾	2,195	(2,203)	53.16
Additional shares reserved	-	-	-
December 31, 2002	4,049	55,419	\$ 38.37
Grants	(803)	803	46.77
Exercises	-	(9,769)	27.26
Cancellations ⁽¹⁾	1,418	(1,418)	45.15
Additional shares reserved	25,000	-	-
June 30, 2003 (Year to date)	29,664	45,035	\$ 40.71

- (1) We currently only grant shares under our amended and restated 1999 Stock Plan. Cancellations from options granted under previous plans are not added back to the shares reserved for issuance under the 1999 Stock Plan.

In-the-Money and Out-of-the-Money Option Information

(Shares in thousands)

As of June 30, 2003	Exercisable		Unexercisable		Total	
	Shares	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price	Shares	Weighted Average Exercise Price
In-the-Money	18,736	\$ 31.43	18,556	\$ 33.85	37,292	\$ 32.63
Out-of-the-Money ⁽¹⁾	4,965	79.74	2,778	79.41	7,743	79.62
Total Options Outstanding	23,701		21,334		45,035	

- (1) Out-of-the-money options are those options with an exercise price equal to or greater than the fair market value of Genentech Common Stock, \$72.12, at the close of business on June 30, 2003.

Distribution and Dilutive Effect of Options

Employee and Executive Officer Option Grants

	2003	2002	2001
Net grants during the year as % of outstanding shares	0.20 %	1.98 %	1.64 %
Grants to Named Executive Officers* during the period as % of outstanding shares	- %	0.25 %	0.22 %
Grants to Named Executive Officers during the year as % of total options granted	- %	10.27 %	10.52 %

- * "Named Executive Officers" refers to our CEO and our four other most highly compensated executive officers as defined under Item 402(a)(3) of Regulation S-K of the federal securities laws.

Equity Compensation Plan Information

All of our equity compensation plans under which options are currently outstanding have been approved by our stockholders.

**FORWARD-LOOKING INFORMATION AND CAUTIONARY FACTORS
THAT MAY AFFECT FUTURE RESULTS**

Because our actual results may differ materially from any forward-looking statements made by or on behalf of Genentech, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our product sales, royalties, contract revenues, expenses, net income and earnings per share.

The Successful Development of Biotherapeutics Is Highly Uncertain and Requires Significant Expenditures

Successful development of biotherapeutics is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Products that appear promising in the early phases of development may fail to reach the market for several reasons including:

- Preclinical and clinical trial results that may show the product to be less effective than desired (e.g., the trial failed to meet its primary objectives) or to have harmful or problematic side effects.
- Failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies, extended length of time to achieve study endpoints, additional time requirements for data analysis or Biologics License Application (or BLA) preparation, discussions with the U.S. Food and Drug Administration (or FDA), an FDA request for additional preclinical or clinical data, or unexpected safety or manufacturing issues.
- Manufacturing costs, pricing or reimbursement issues, or other factors that make the product uneconomical.
- The proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.

Success in preclinical and early clinical trials does not ensure that large-scale clinical trials will be successful. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly and may be difficult to predict.

Factors affecting our research and development (or R&D) expenses include, but are not limited to:

- The number of and the outcome of clinical trials currently being conducted by us and/or our collaborators. For example, our R&D expenses may increase based on the number of late-stage clinical trials being conducted by us and/or our collaborators.
- The number of products entering into development from late-stage research. For example, there is no guarantee that internal research efforts will succeed in generating sufficient data for us to make a positive development decision or that an external candidate will be available on terms acceptable to us. In the past, some promising candidates did not yield sufficiently positive preclinical results to meet our stringent development criteria.
- Hoffmann-La Roche's decisions whether to exercise its options to develop and sell our future products in non-U.S. markets and the timing and amount of any related development cost reimbursements.

- In-licensing activities, including the timing and amount of related development funding or milestone payments. For example, we may enter into agreements requiring us to pay a significant upfront fee for the purchase of in-process research and development (or IPR&D), which we may record as an R&D expense.
- As part of our strategy, we invest in R&D. R&D as a percentage of revenues can fluctuate with the changes in future levels of revenue. Lower revenues can lead to more limited spending on R&D efforts.
- Future levels of revenue.

We May Be Unable to Obtain or Maintain Regulatory Approvals for Our Products

The biotechnology and pharmaceutical industries are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities. Of particular significance are the FDA's requirements covering R&D, testing, manufacturing, quality control, labeling and promotion of drugs for human use. A biotherapeutic cannot be marketed in the United States until it has been approved by the FDA, and then can only be marketed for the indications and claims approved by the FDA. As a result of these requirements, the length of time, the level of expenditures and the laboratory and clinical information required for approval of a New Drug Application (or NDA) or a BLA, are substantial and can require a number of years. In addition, after any of our products receive regulatory approval, they remain subject to ongoing FDA regulation, including, for example, changes to the product label, new or revised regulatory requirements for manufacturing practices, written advisements to physicians and a product recall.

We cannot be sure that we can obtain necessary regulatory approvals on a timely basis, if at all, for any of the products we are developing or manufacturing or that we can maintain necessary regulatory approvals for our existing products, and all of the following could have a material adverse effect on our business:

- Significant delays in obtaining or failing to obtain required approvals as described in "The Successful Development of Biotherapeutics is Highly Uncertain" above.
- Loss of, or changes to, previously obtained approvals.
- Failure to comply with existing or future regulatory requirements.
- Changes to manufacturing processes, manufacturing process standards or Good Manufacturing Practices following approval or changing interpretations of these factors.

Moreover, it is possible that the current regulatory framework could change or additional regulations could arise at any stage during our product development or marketing, which may affect our ability to obtain or maintain approval of our products.

Difficulties or Delays in Product Manufacturing Could Harm Our Business

We currently produce all of our products at our manufacturing facilities located in South San Francisco, California and Vacaville, California or through various contract manufacturing arrangements. Problems with any of our or our contractors' manufacturing processes could result in failure to produce adequate product supplies or product defects, which could require us to delay shipment of products, recall products previously shipped or be unable to supply products at all.

In addition, any prolonged interruption in the operations of our or our contractors' manufacturing facilities could result in cancellations of shipments, loss of product in the process of being manufactured, or a shortfall of available product inventory. A number of factors could cause interruptions, including equipment malfunctions or failures, damage to a facility due to natural disasters, including earthquakes as our South San Francisco facilities are located in an area where earthquakes could occur, changes in FDA regulatory requirements or standards that require modifications to our manufacturing processes, action by the FDA that results in the halting of production of one or more of our products due to regulatory issues, a contract manufacturer going out of business or other similar factors.

Page 36

Because our manufacturing processes and those of our contractors are highly complex and are subject to a lengthy FDA approval process, alternative qualified production capacity may not be available on a timely basis or at all. Difficulties or delays in our and our contractors' manufacturing and supply of existing or new products could increase our costs, cause us to lose revenue or market share and damage our reputation.

We may also experience insufficient available capacity to manufacture existing or new products which could cause shortfalls of available product inventory or we may have an excess of available capacity which could lead to an idling of a portion of our manufacturing facilities and incurring idle plant costs, resulting in an increase in our costs of sales.

Protecting Our Proprietary Rights Is Difficult and Costly

The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. Accordingly, we cannot predict the breadth of claims allowed in these companies' patents. Patent disputes are frequent and can preclude the commercialization of products. We have in the past been, are currently, and may in the future be, involved in material patent litigation, such as the matters discussed in Note 2, "Leases and Contingencies," in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Form 10-Q. Patent litigation is costly in its own right and could subject us to significant liabilities to third parties. In addition, an adverse decision could force us to either obtain third-party licenses at a material cost or cease using the technology or product in dispute.

The presence of patents or other proprietary rights belonging to other parties may lead to our termination of the R&D of a particular product.

We believe that we have strong patent protection or the potential for strong patent protection for a number of our products that generate sales and royalty revenue or that we are developing. However, it is for the courts in the U.S. and in other jurisdictions ultimately to determine the strength of that patent protection.

The Outcome of, and Costs Relating to, Pending Litigation Are Uncertain

Litigation to which we are currently or have been subjected relates to, among other things, our patent and other intellectual property rights, licensing arrangements with other persons, product liability and financing activities. We cannot predict with certainty the eventual outcome of pending litigation, which may include an injunction against the manufacture or sale of a product or potential product or a significant jury verdict or punitive damages award, or a judgment that certain of our patent or other intellectual property rights are invalid or unenforceable. Furthermore, we may have to incur substantial expense in defending these lawsuits.

We May Be Unable to Retain Skilled Personnel and Maintain Key Relationships

The success of our business depends, in large part, on our continued ability to attract and retain highly qualified management, scientific, manufacturing and sales and marketing personnel, and on our ability to develop and maintain important relationships with leading research institutions and key distributors. Competition for these types of personnel and relationships is intense.

Roche has the right to maintain its percentage ownership interest in our common stock. Our affiliation agreement with Roche provides that, among other things, we will establish a stock repurchase program designed to maintain Roche's percentage ownership in our common stock if we issue or sell any shares. This could have an effect on the number of shares we are able to grant under our stock option plans. We therefore cannot assure you that we will be able to attract or retain skilled personnel or maintain key relationships.

We Face Growing and New Competition

We face growing competition in two of our therapeutic markets and expect new competition in a third market. First, in the thrombolytic market, Activase has lost market share and could lose additional market share to Centocor's Retavase® either alone or in combination with the use of another Centocor product, ReoPro®

Page 37

(abciximab) and to the use of mechanical reperfusion therapies to treat acute myocardial infarction; the resulting adverse effect on sales has been and could continue to be material. Retavase received approval from the FDA in October 1996 for the treatment of acute myocardial infarction. We expect that the use of mechanical reperfusion in lieu of thrombolytic therapy for the treatment of acute myocardial infarction will continue to grow. In addition, we face potential increased competition in the catheter clearance market from the reintroduction of Abbott Laboratories' Abbokinase® (urokinase).

Second, in the growth hormone market, we continue to face competition from other companies currently selling growth hormone products and delivery devices. As a result of that competition, we have experienced a loss in market share in the past. Competitors have also received approval to market their existing human growth hormone products for additional indications. As a result of this competition, market share of our growth hormone products may decline. In addition, we have certain patents related to the production of growth hormone that have expired or are expiring soon and as a consequence those patents would no longer exclude others from making growth hormone using the processes claimed by those patents.

Third, in the non-Hodgkin's lymphoma market, Corixa Corporation received FDA approval in June 2003, for Bexxar™ (tositumomab and iodine I 131 tositumomab), which may potentially compete with our product Rituxan. IDEC received marketing approval from the FDA and began commercial shipments in late March 2002 for Zevalin™ (ibritumomab tiuxetan), a product which could also potentially compete with Rituxan. Both Bexxar and Zevalin are radiolabeled molecules while Rituxan is not. We are also aware of other potentially competitive biologic therapies for non-Hodgkin's lymphoma in development.

Other Factors Could Affect Our Product Sales

Other factors that could affect our product sales include, but are not limited to:

- The timing of FDA approval, if any, of competitive products.
- Our pricing decisions, including a decision to increase or decrease the price of a product, and the pricing decisions of our competitors.
- Government and third-party payer reimbursement and coverage decisions that affect the utilization of our products and competing products.
- Negative data from new clinical studies could cause the utilization and sales of our products to decrease.
- The degree of patent protection afforded our products by patents granted to us and by the outcome of litigation involving our patents.
- The outcome of litigation involving patents of other companies concerning our products or processes related to production and formulation of those products or uses of those products. For example, as described in Note 2, "Leases and Contingencies," in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q, at various times other companies have filed patent infringement lawsuits against us alleging that the manufacture, use and sale of certain of our products infringe their patents.
- The increasing use and development of alternate therapies. For example, the overall size of the market for thrombolytic therapies, such as our Activase product, continues to decline as a result of the increasing use of mechanical reperfusion.
- The rate of market penetration by competing products. For example, we have lost market share to new competitors in the thrombolytic and, in the past, growth hormone markets.

Our Royalty and Contract Revenues Could Decline

Royalty and contract revenues in future periods could vary significantly. Major factors affecting these revenues include, but are not limited to:

- Hoffmann-La Roche's decisions whether to exercise its options and option extensions to develop and sell our future products in non-U.S. markets and the timing and amount of any related development cost reimbursements.
- Variations in Hoffmann-La Roche's sales and other licensees' sales of licensed products.
- The expiration or termination of existing arrangements with other companies and Hoffmann-La Roche, which may include development and marketing arrangements for our products in the U.S., Europe and other countries outside the United States.
- The timing of non-U.S. approvals, if any, for products licensed to Hoffmann-La Roche and to other licensees.
- Fluctuations in foreign currency exchange rates.

- The initiation of new contractual arrangements with other companies.
- Whether and when contract benchmarks are achieved.
- The failure of or refusal of a licensee to pay royalties.
- The expiration or invalidation of our patents or licensed intellectual property.
- Decreases in licensees' sales of product due to competition, manufacturing difficulties or other factors that affect the sales of product.

We May Incur Material Product Liability Costs

The testing and marketing of medical products entail an inherent risk of product liability. Liability exposures for biotherapeutics could be extremely large and pose a material risk. Our business may be materially and adversely affected by a successful product liability claim or claims in excess of any insurance coverage that we may have.

Insurance Coverage Is Increasingly More Difficult to Obtain or Maintain

While we currently have insurance for our business, property and our products, first- and third-party insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to third-party claims or suffer a loss or damage in excess of our insurance coverage, we may be required to share that risk in excess of our insurance limits. Furthermore, any first- or third-party claims made on our insurance policy may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all in the future.

Environmental and Other Risks

We generally deal with some hazardous materials in connection with our research and manufacturing activities. In the event such hazardous materials are stored, handled or released into the environment in violation of law or any permit, we could be subject to loss of our permits, government fines or penalties and/or other adverse governmental action. The levy of a substantial fine or penalty, the payment of significant environmental remediation costs or the loss of a permit or other authorization to operate or engage in our ordinary course of business could materially adversely affect our business.

Fluctuations in Our Operating Results Could Affect the Price of Our Common Stock

Our operating results may vary from period to period for several reasons including:

- The overall competitive environment for our products as described in "We Face Growing and New Competition" above.
- The amount and timing of sales to customers in the United States. For example, sales of a product may increase or decrease due to pricing changes, fluctuations in distributor buying patterns or sales initiatives that we may undertake from time to time.

- The amount and timing of our sales to Hoffmann-La Roche and our other collaborators of products for sale outside of the United States and the amount and timing of sales to their respective customers, which directly impact both our product sales and royalty revenues.
- The timing and volume of bulk shipments to licensees.
- The availability and extent of government and private third-party reimbursements for the cost of therapy.
- The extent of product discounts extended to customers.
- The effectiveness and safety of our various products as determined both in clinical testing and by the accumulation of additional information on each product after it is approved by the FDA for sale.
- The rate of adoption and use of our products for approved indications and additional indications. Among other things, the rate of adoption and use of our products may be affected by results of clinical studies reporting on the benefits or risks of a product.
- The potential introduction of new products and additional indications for existing products.
- The ability to successfully manufacture sufficient quantities of any particular marketed product.
- The number and size of any product price increases we may issue.

Our Stock Price, Like That of Many Biotechnology Companies, Is Highly Volatile

The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. In addition, the market price of our common stock has been and may continue to be volatile.

In addition, the following factors may have a significant impact on the market price of our common stock:

- Announcements of technological innovations or new commercial products by us or our competitors.
- Developments or outcome of litigation, including litigation regarding proprietary and patent rights.
- Publicity regarding actual or potential medical results relating to products under development or being commercialized by us or our competitors.
- Regulatory developments or delays concerning our products in the United States and foreign countries.
- Issues concerning the safety of our products or of biotechnology products generally.
- Economic and other external factors or a disaster or crisis.

- Period-to-period fluctuations in our financial results.

In Connection with the Redemption of Our Special Common Stock, We Recorded Substantial Goodwill and Other Intangibles, the Amortization or Impairment of Which May Adversely Affect Our Earnings

As a result of the redemption of our Special Common Stock, Roche owned all of our outstanding common stock. Consequently, push-down accounting under generally accepted accounting principles in the U.S. was required. Push-down accounting required us to establish a new accounting basis for our assets and liabilities, based on Roche's cost in acquiring all of our stock. In other words, Roche's cost of acquiring Genentech was "pushed down" to us and reflected on our financial statements. Push-down accounting required us to record goodwill of approximately \$1,685.7 million and other intangible assets of \$1,499.0 million on June 30, 1999. The other intangible assets are being amortized over their estimated useful lives ranging from 5 to 15 years. See Note 4, "Goodwill and Other Intangible Assets" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further information on these other intangible assets.

Statement of Financial Accounting Standards (or FAS) No. 142, "Goodwill and Other Intangible Assets," which was adopted January 1, 2002, requires that goodwill not be amortized, but rather be subject to an impairment test at least annually. Separately identified and recognized intangible assets resulting from business combinations completed before July 1, 2001, that did not meet the new criteria under FAS 141, "Business Combinations," for separate recognition of intangible assets have been reclassified into goodwill upon adoption. These intangible assets included our trained and assembled workforce. In addition, the useful lives of recognized intangible assets acquired in transactions completed before July 1, 2001, will be reassessed at each reporting date and the remaining amortization periods adjusted accordingly. At least annually, we will evaluate whether events and circumstances have occurred that indicate the remaining balance of goodwill and other intangible assets may not be recoverable. If our evaluation of the assets results in a possible impairment, we may have to reduce the carrying value of our intangible assets. This could have a material adverse effect on our financial condition and results of operations during the periods in which we recognize a reduction. We may have to write down intangible assets in future periods. We performed an impairment test of goodwill at transition on January 1, 2002, and an annual impairment test on September 30, 2002, and found no impairment. For more information, see Note 3, "Relationship With Roche -- Redemption of Our Special Common Stock" and Note 4, "Goodwill and Other Intangible Assets" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Future Stock Repurchases Could Adversely Affect Our Cash Position

On October 31, 2001, our Board of Directors authorized a stock repurchase program to repurchase up to 13.0 million shares for an amount not to exceed \$625.0 million of our common stock over a 12-month period. On August 15, 2002, our Board of Directors authorized an extension of the stock repurchase program through June 30, 2003, for the repurchase of additional shares for an amount not to exceed an additional \$375.0 million of our common stock, increasing the program to a total of approximately 29.6 million shares and an amount not to exceed a total of \$1.0 billion. Purchases by Genentech could be made in the open market or in privately negotiated transactions from time to time at management's discretion. Genentech could also engage in transactions in other Genentech securities in conjunction with the repurchase program, including derivative securities. Genentech also entered into a 10b5-1 insider trading plan on February 8, 2002, to repurchase shares in the open market during those periods each quarter when trading in our stock by insiders is restricted under our insider trading policy. Under its terms, Genentech's 10b5-1 plan terminated on October 11, 2002, the date on which a total of 3.0 million shares had been purchased under the plan during the period from February 8, 2002 to October 11, 2002. Due to the extension of the stock repurchase program, Genentech entered into a new 10b5-1 trading plan on November 13, 2002, to repurchase shares in the open market during those periods each quarter when trading in our stock is restricted under our insider trading policy. This plan covered 2.5 million shares. Under the stock repurchase program, we repurchased approximately 2.2 million shares of our common stock in the second quarter of 2003 at a cost of approximately \$82.1 million and approximately 5.4 million shares of our common stock in the first six months of 2003 at a cost of approximately \$195.3 million. Of those shares repurchased, the number of shares repurchased under Genentech's 10b5-1 insider trading plan were approximately 0.3 million in the second quarter of 2003 and approximately 1.5 million in the first six months of 2003.

We repurchased approximately 8.3 million shares of our common stock in the second quarter of 2002 at a cost of approximately \$311.4 million and approximately 12.0 million shares of our common stock during

the first six months of 2002 at a cost of approximately \$491.2 million. Of those shares repurchased, the number of shares repurchased under Genentech's 10b5-1 insider trading plan were 1.1 million during the second quarter of 2002 and 1.4 million during the first six months of 2002. Under the stock repurchase program, we repurchased approximately 23.8 million shares of our common stock at a cost of approximately \$893.7 million during the period from November 1, 2001, through June 30, 2003. The stock repurchase program expired on June 30, 2003 and has not been extended.

While the dollar amounts associated with a stock repurchase program cannot currently be estimated, stock repurchases could have a material adverse impact on our liquidity, credit rating and ability to access additional capital in the financial markets.

Our Affiliation Agreement with Roche Could Adversely Affect Our Cash Position

Our affiliation agreement with Roche provides that we establish a stock repurchase program designed to maintain Roche's percentage ownership interest in our common stock based on an established Minimum Percentage. For more information on our stock repurchase program, see Note 9, "Capital Stock" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q. See Note 3, "Relationship With Roche -- Roche's Ability to Maintain Its Percentage Ownership Interest in Our Stock" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for information regarding the Minimum Percentage.

While the dollar amounts associated with these future stock repurchases cannot currently be estimated, stock repurchases could have a material adverse effect on our cash position, and may have the effect of limiting our ability to use our capital stock as consideration for acquisitions.

Future Sales of Our Common Stock by Roche Could Cause the Price of Our Common Stock to Decline

As of June 30, 2003, Roche owned 306,594,352 shares of our common stock or 59.2% of our outstanding shares. All of our shares owned by Roche are eligible for sale in the public market subject to compliance with the applicable securities laws. We have agreed that, upon Roche's request, we will file one or more registration statements under the Securities Act in order to permit Roche to offer and sell shares of our common stock. Sales of a substantial number of shares of our common stock by Roche in the public market could adversely affect the market price of our common stock.

Roche Holdings, Inc., Our Controlling Stockholder, May Have Interests That Are Adverse to Other Stockholders

Roche as our majority stockholder, controls the outcome of actions requiring the approval of our stockholders. Our bylaws provide, among other things, that the composition of our board of directors shall consist of two Roche directors, three independent directors nominated by a nominating committee and one Genentech employee nominated by the nominating committee. As long as Roche owns in excess of 50% of our common stock, Roche directors will comprise two of the three members of the nominating committee. However, at any time until Roche owns less than 5% of our stock, Roche will have the right to obtain proportional representation on our board. Roche intends to continue to allow our current management to conduct our business and operations as we have done in the past.

However, we cannot assure stockholders that Roche will not institute a new business plan in the future. Roche's interests may conflict with minority shareholder interests.

Our Affiliation Agreement with Roche Could Limit Our Ability to Make Acquisitions and Could Have a Material Negative Impact on Our Liquidity

The affiliation agreement between us and Roche contains provisions that:

- Require the approval of the directors designated by Roche to make any acquisition or any sale or disposal of all or a portion of our business representing 10% or more of our assets, net income or revenues.
- Enable Roche to maintain its percentage ownership interest in our common stock.

Page 42

- Require us to establish a stock repurchase program designed to maintain Roche's percentage ownership interest in our common stock based on an established Minimum Percentage. For information regarding Minimum Percentage, see Note 3, "Relationship With Roche -- Roche's Ability to Maintain Its Percentage Ownership Interest in Our Stock" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q. For more information on our stock repurchase program, see Note 9, "Capital Stock" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

These provisions may have the effect of limiting our ability to make acquisitions and while the dollar amounts associated with a stock repurchase program cannot currently be estimated, stock repurchases could have a material adverse impact on our liquidity, credit rating and ability to access additional capital in the financial markets.

Our Stockholders May Be Unable to Prevent Transactions That Are Favorable to Roche but Adverse to Us

Our certificate of incorporation includes provisions relating to:

- Competition by Roche with us.
- Offering of corporate opportunities.
- Transactions with interested parties.
- Intercompany agreements.
- Provisions limiting the liability of specified employees.

Our certificate of incorporation provides that any person purchasing or acquiring an interest in shares of our capital stock shall be deemed to have consented to the provisions in the certificate of incorporation relating to competition with Roche, conflicts of interest with Roche, the offer of corporate opportunities to Roche and intercompany agreements with Roche. This deemed consent may restrict the ability to challenge transactions carried out in compliance with these provisions.

Potential Conflicts of Interest Could Limit Our Ability to Act on Opportunities That Are Adverse to Roche

Persons who are directors and/or officers of Genentech and who are also directors and/or officers of Roche may decline to take action in a manner that might be favorable to us but adverse to Roche. Two of our directors, Dr. Franz B. Humer and Dr. Jonathan K.C. Knowles, currently serve as officers and employees of Roche Holding Ltd and its affiliates, and Dr. Humer is a director of Roche Holding Ltd.

We Are Exposed to Market Risk

We are exposed to market risk, including changes to interest rates, foreign currency exchange rates and equity investment prices. To reduce the volatility relating to these exposures, we enter into various derivative hedging transactions pursuant to our investment and risk management policies and procedures. We do not use derivatives for speculative purposes.

We maintain risk management control systems to monitor the risks associated with interest rates, foreign currency exchange rates and equity investment price changes, and our derivative and financial instrument positions. The risk management control systems use analytical techniques, including sensitivity analysis and market values. Though we intend for our risk management control systems to be comprehensive, there are inherent risks that may only be partially offset by our hedging programs should there be unfavorable movements in interest rates, foreign currency exchange rates or equity investment prices.

The estimated exposures discussed below are intended to measure the maximum amount we could lose from adverse market movements in interest rates, foreign currency exchange rates and equity investment prices, given a specified confidence level, over a given period of time. Loss is defined in the value at risk estimation as fair market

value loss. The exposures to interest rate, foreign currency exchange rate and equity investment price changes are calculated based on proprietary modeling techniques from a Monte Carlo simulation value at risk model using a 21-trading days holding period and a 95% confidence level. The value at risk model assumes non-linear financial returns and generates potential paths various market prices could take and tracks the hypothetical performance of a portfolio under each scenario to approximate its financial return. The value at risk model takes into account correlations and diversification across market factors, including interest rates, foreign currencies and equity prices. Hedge instruments are modeled as positions on the actual underlying securities. No proxies were used. Market volatilities and correlations are based on one year historical times-series provided by J.P. Morgan Riskmetrics™ as of December 31, 2002.

Our Interest Income Is Subject to Fluctuations in Interest Rates

Our material interest-bearing assets, or interest-bearing portfolio, consisted of cash, cash equivalents, restricted cash, short-term investments, convertible preferred stock investments, nonmarketable debt securities, long-term investments and interest-bearing forward contracts. The balance of our interest-bearing portfolio, including restricted and unrestricted cash, was \$2,400.9 million or 32% of total assets at June 30, 2003. Interest income related to this portfolio was \$40.1 million in the first six months of 2003. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. In this regard, changes in U.S. interest rates affect the interest-bearing portfolio. To mitigate the impact of fluctuations in U.S. interest rates, for a portion of our portfolio, we may enter into swap transactions which involve the receipt of fixed rate interest and the payment of floating rate interest without the exchange of the underlying principal.

Based on our overall interest rate exposure at December 31, 2002, including derivative and other interest rate sensitive instruments, a near-term change in interest rates, within a 95% confidence level based on historical interest rate movements could result in a potential loss in fair value of our interest rate sensitive instruments of \$14.1 million.

We Are Exposed to Risks Relating to Foreign Currency Exchange Rates and Foreign Economic Conditions

We receive royalty revenues from licensees selling products in countries throughout the world. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which our licensed products are sold. We are exposed to changes in exchange rates in Europe, Asia (primarily Japan) and Canada. Our exposure to foreign exchange rates primarily exists with the Swiss franc. When the dollar strengthens against the currencies in these countries, the dollar value of foreign-currency denominated revenue decreases; when the dollar weakens, the dollar value of the foreign-currency denominated revenues increases. Accordingly, changes in exchange rates, and in particular a strengthening of the dollar, may adversely affect our royalty revenues as expressed in dollars. Exchange rate exposures on these royalties are being offset by expenses arising from our foreign manufacturing facility as well as non-dollar expenses incurred in our collaborations. Currently, our foreign royalty revenues exceed our foreign expenses. In addition, as part of our overall investment strategy, a portion of our portfolio is primarily in non-dollar denominated investments. As a result, we are exposed to changes in the exchange rates of the countries in which these non-dollar denominated investments are made.

To mitigate our net foreign exchange exposure, our policy allows us to hedge certain of our anticipated royalty revenues by purchasing option contracts with expiration dates and amounts of currency that are based on 25% to 90% of probable future revenues so that the potential adverse impact of movements in currency exchange rates on the non-dollar denominated revenues will be at least partly offset by an associated increase in the value of the option. Generally, the term of these options is one to five years. To hedge the non-dollar expenses arising from our foreign manufacturing facility, we may enter into forward contracts to lock in the dollar value of a portion of these anticipated expenses.

Based on our overall currency rate exposure at December 31, 2002, including derivative and other foreign currency sensitive instruments, a near-term change in currency rates within a 95% confidence level based on historical currency rate movements would not materially affect the fair value of our foreign currency sensitive instruments.

Our Investments in Equity Securities Are Subject to Market Risks

As part of our strategic alliance efforts, we invest in equity instruments of biotechnology companies. Our biotechnology equity investment portfolio totaled \$287.3 million or 4% of total assets at June 30, 2003. These investments are subject to fluctuations from market value changes in stock prices. For example, in 2002, we recorded charges related to the write-down of certain equity security investments that had other than temporary impairments.

To mitigate the risk of market value fluctuation, certain equity securities are hedged with zero-cost collars and forward contracts. A zero-cost collar is a purchased put option and a written call option in which the cost of the purchased put and the proceeds of the written call offset each other; therefore, there is no initial cost or cash outflow for these instruments at the time of purchase. The purchased put protects us from a decline in the market value of the security below a certain minimum level (the put "strike" level), while the call effectively limits our potential to benefit from an increase in the market value of the security above a certain maximum level (the call "strike" level). A forward

contract is a derivative instrument where we lock-in the termination price we receive from the sale of stock based on a pre-determined spot price. The forward contract protects us from a decline in the market value of the security below the spot price and limits our potential benefit from an increase in the market value of the security above the spot price. Throughout the life of the contract, we receive interest income based on the notional amount and a floating-rate index. In addition, as part of our strategic alliance efforts, we hold convertible preferred stock, including dividend-bearing convertible preferred stock, and have made interest-bearing loans that are convertible into the equity securities of the debtor or repaid in cash. Depending on market conditions, we may determine that in 2003 certain of our other unhedged equity security investments are impaired, which would result in additional write-downs of those equity security investments.

Based on our overall exposure to fluctuations from market value changes in marketable equity prices at December 31, 2002, a near-term change in equity prices within a 95% confidence level based on historic volatilities could result in a potential loss in fair value of our equity securities portfolio of \$23.0 million.

We Are Exposed to Credit Risk of Counterparties

We could be exposed to losses related to the financial instruments described above should one of our counterparties default. We attempt to mitigate this risk through credit monitoring procedures.

The Company's Effective Tax Rate May Vary Significantly

Various internal and external factors may have favorable or unfavorable effects on our future effective tax rate. These factors include but are not limited to changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, future levels of R&D spending, future levels of capital expenditures, and changes in overall levels of pretax earnings.

New and Potential New Accounting Pronouncements May Impact Our Future Financial Position and Results of Operations

In November 2002, the Emerging Issues Task Force (or EITF) of the Financial Accounting Standards Board (or FASB) issued EITF 00-21, "Revenue Arrangements with Multiple Deliverables," which addresses certain aspects of the accounting for arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. Under EITF 00-21, revenue arrangements with multiple deliverables should be divided into separate units of accounting if the deliverables meet certain criteria, including whether the fair value of the delivered items can be determined and whether there is evidence of fair value of the undelivered items. In addition, the consideration should be allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria should be considered separately for each of the separate units of accounting. EITF 00-21 is effective for revenue arrangements we enter into after June 30, 2003. We are currently evaluating the impact of EITF 00-21 on revenue arrangements we enter into in the future, which will need to comply with EITF 00-21.

In November 2002, the FASB issued Interpretation No. 45 (or FIN 45), "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN 45 elaborates on the existing disclosure requirements for most guarantees, including residual value guarantees issued in conjunction with operating lease agreements. It also clarifies that at the time a company issues a guarantee, the company must recognize an initial liability for the fair value of the obligation it assumes under that guarantee and must disclose that

information in its interim and annual financial statements. The initial recognition and initial measurement provisions apply on a prospective basis to guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. Our adoption of FIN 45 did not have a material impact on our results of operations and financial position. See above in "Leases and Contingencies" for a discussion of our synthetic leases and the related residual value guarantees and our exposure related to our agreement with Serono S.A.

In January 2003, the FASB issued Interpretation No. 46 (or FIN 46), "Consolidation of Variable Interest Entities." FIN 46 requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. A variable interest entity is a corporation, partnership, trust, or any other legal structures used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A variable interest entity often holds financial assets, including loans or receivables, real estate or other property. A variable interest entity may be essentially passive or it may engage in research and development or other activities on behalf of another entity. The consolidation requirements of FIN 46 apply to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply to all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. See above in "Leases and Contingencies" for a discussion of our synthetic leases and the expanded disclosures.

In December 2002, the FASB issued Statement No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure." FAS 148 amends FAS 123 "Accounting for Stock-Based Compensation" to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, FAS 148 amends the disclosure requirements of FAS 123 to require more prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The additional disclosure requirements of FAS 148 are effective for fiscal years ending after December 15, 2002. We have elected to continue to follow the intrinsic value method of accounting as prescribed by Accounting Principles Board Opinion No. 25 (or APB 25), "Accounting for Stock Issued to Employees," to account for employee stock options. Under APB 25, no compensation expense is recognized unless the exercise price of our employee stock options is less than the market price of the underlying stock on the date of grant. We have not recorded such expenses in the periods presented because we grant options at the fair market value of the underlying stock on the date of grant. See Note 1, "Summary of Significant Accounting Policies" in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for the required disclosures under FAS 148.

There may be potential new accounting pronouncements or regulatory rulings which may have an impact on our future financial position and results of operations. In particular, there are a number of rule changes and proposed legislative initiatives following the recent corporate bankruptcies and failures which could result in changes in accounting rules, including the accounting for employee stock options as an expense. These and other potential changes could materially impact our assets and liabilities, and the expenses we report under generally accepted accounting principles, and could adversely affect our operating results or financial condition.

Our market risks at June 30, 2003 have not changed significantly from those discussed in Item 7A of our Form 10-K for the year ended December 31, 2002 on file with the Securities and Exchange Commission. See Note 5, "Derivative Financial Instruments," in the Notes to Condensed Consolidated Financial Statements in Part I, Item 1 and the "Forward-Looking Information and Cautionary Factors That May Affect Future Results -- We Are Exposed to Market Risk" section of Item 2 of this Form 10-Q for additional discussions of our market risks.

Item 4. Controls and Procedures

The Company's principal executive and financial officers reviewed and evaluated the Company's disclosure controls and procedures (as defined in Exchange Act Rule 13a-15 and 15(d)-15) as of the end of the period covered by this Form 10-Q. Based on that evaluation, the Company's principal executive and financial officers concluded that the Company's disclosure controls and procedures are effective in timely providing them with material information relating to the Company, as required to be disclosed in the reports the Company files under the Exchange Act.

Page 47

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are a party to various legal proceedings, including patent infringement litigation relating to our antibody products, and licensing and contract disputes, and other matters.

In the shareholder derivative suit filed by Green Equity, LLC, following the filing of an amended complaint by plaintiffs, defendants again filed motions to dismiss. On June 20, 2003, the Court granted the defendants' motions in their entirety and the entire action was dismissed on the merits against all defendants.

In the arbitration proceeding between Genentech and Tanox, a decision in the arbitration has been delayed and is expected no earlier than July 31, 2003.

See also Item 3 of our report on Form 10-K for the period ended December 31, 2002 and Part II, Item 1 of our report on Form 10-Q for the period ended March 31, 2003.

See also Note 2, "Leases and Contingencies," note in the Notes to Condensed Consolidated Financial Statements of Part I.

Item 4. Submission of Matters to a Vote of Security Holders

At Genentech's Annual Meeting of Stockholders held on April 23, 2003, three matters were voted upon. A description of each matter and a tabulation of the votes for each of the matters follows:

1. To elect six directors for a term of one year or until such directors' successors are elected and qualified:

Nominee	Votes	
	For	Withheld
Herbert W. Boyer, Ph.D.	421,593,880	60,972,175
Franz B. Humer, Doctor of Law	419,735,389	62,830,666
Jonathan K.C. Knowles, Ph.D.	418,667,124	63,898,931
Arthur D. Levinson, Ph.D.	478,767,742	3,798,313
Sir Mark Richmond, Ph.D.	469,565,041	13,001,014
Charles A. Sanders, M.D.	469,562,722	13,003,333

There were no broker nonvotes.

- To approve the amended and restated 1999 Stock Plan.

Votes		
For	Against	Abstain
412,999,857	34,061,247	225,430

There were 35,279,521 broker nonvotes.

- To approve an amendment to the amended 1991 Employee Stock Plan.

Votes		
For	Against	Abstain
436,587,173	10,501,552	197,810

There were 35,279,520 broker nonvotes.

Page 48

- To ratify the appointment of Ernst & Young LLP as Genentech's independent auditors for the fiscal year ending December 31, 2003:

Votes		
For	Against	Abstain
479,474,014	2,984,835	107,206

There were no broker nonvotes.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

- (i) 15.1 Letter regarding Unaudited Interim Financial Information.

- (ii) 99.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
- (iii) 99.2 Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
- (iv) 99.3 Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K.

On April 9, 2003, we filed a Report on Form 8-K under Item 5 - Other Events, reporting the issuance of a press release, announcing our earnings for the quarter ended March 31, 2003.

Page 49

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GENENTECH, INC.

Date: July 22, 2003

/s/ARTHUR D. LEVINSON

Arthur D. Levinson, Ph.D.
Chairman, President and
Chief Executive Officer

Date: July 22, 2003

/s/LOUIS J. LAVIGNE, JR.

Louis J. Lavigne, Jr.
Executive Vice President and
Chief Financial Officer

Date: July 22, 2003

/s/JOHN M. WHITING

John M. Whiting
Vice President, Controller and
Chief Accounting Officer